

# IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents

Journal of the International Association of Providers of AIDS Care  
1–32

© The Author(s) 2015  
Reprints and permission:  
sagepub.com/journalsPermissions.nav  
DOI: 10.1177/2325957415613442  
jiapac.sagepub.com



## International Advisory Panel on HIV Care Continuum Optimization<sup>1</sup>

### Abstract

**Background:** An estimated 50% of people living with HIV (PLHIV) globally are unaware of their status. Among those who know their HIV status, many do not receive antiretroviral therapy (ART) in a timely manner, fail to remain engaged in care, or do not achieve sustained viral suppression. Barriers across the HIV care continuum prevent PLHIV from achieving the therapeutic and preventive effects of ART. **Methods:** A systematic literature search was conducted, and 6132 articles, including randomized controlled trials, observational studies with or without comparators, cross-sectional studies, and descriptive documents, met the inclusion criteria. Of these, 1047 articles were used to generate 36 recommendations to optimize the HIV care continuum for adults and adolescents. **Recommendations:** Recommendations are provided for interventions to optimize the HIV care environment; increase HIV testing and linkage to care, treatment coverage, retention in care, and viral suppression; and monitor the HIV care continuum.

### Keywords

HIV, continuum of care, testing, antiretroviral therapy, viral suppression

### Introduction

Modern antiretroviral therapy (ART) has dramatically changed the course of HIV disease. Today, a person diagnosed with HIV at the age of 20 years if started promptly on ART is expected to live a normal life span, with a highly preserved quality of life.<sup>1</sup> Antiretroviral therapy is also highly effective in preventing the sexual,<sup>2</sup> parenteral,<sup>3</sup> and vertical<sup>4</sup> transmission of HIV. These medical breakthroughs fostered the development of a treatment as prevention (TasP) strategy,<sup>5,6</sup> whose aim is to provide early access to HIV testing and treatment to prevent progression to AIDS and premature death as well as HIV transmission.<sup>7</sup>

The United Nations (UN) has formally embraced TasP as it proposed a new global target for HIV treatment referred to as the 90-90-90 targets.<sup>8</sup> The new targets propose that by 2020, 90% of all people living with HIV (PLHIV) should know their HIV serostatus, 90% of people who know their HIV-positive status should be receiving sustained ART, and 90% of people on ART should achieve sustained viral suppression.<sup>8</sup> Modeling suggests that meeting the 90-90-90 targets by 2020 may decrease AIDS incidence, AIDS-related deaths, and new HIV infections by 90% from 2010 levels by 2030.<sup>8</sup>

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), an estimated 15 million PLHIV were on ART by mid-2015—about 50% of the estimated number of diagnosed PLHIV—and less than 25% of those on ART were virologically suppressed.<sup>9,10</sup> The number of PLHIV who are

diagnosed, on ART, and achieving viral suppression reflect 3 distinct points of patient engagement along the HIV care continuum, also referred to as the cascade of care,<sup>11</sup> with viral suppression as the ultimate clinical goal to improve individual PLHIV health outcomes and reduce HIV acquisition and transmission, thus conferring community and public health benefits.

Efforts are needed to optimize the HIV care continuum in order to attain the 90-90-90 targets. Key to these efforts will be to overcome and/or eliminate legal, social, environmental, and structural barriers that prevent PLHIV from accessing and utilizing HIV services.<sup>12</sup> The International Association of Providers of AIDS Care (IAPAC), through a multidisciplinary panel of international advisors, developed the first comprehensive, evidence-based guidelines for optimizing the HIV care continuum, with an aim to increase HIV testing coverage, linkage to care, treatment coverage, engagement and retention in care, and viral suppression for adults and adolescents (persons aged 10-19 years).

<sup>1</sup> A list of the members of the International Advisory Panel on HIV Care Continuum Optimization is available in the About the Authors section.

### Corresponding Author:

José M. Zuniga, International Association of Providers of AIDS Care, 1990 M Street NW, Suite 380, Washington, DC 20036, USA.  
Email: jzuniga@iapac.org

## Guidelines Focus and Target Audience

These guidelines focus on clinical, behavioral, social, and structural interventions to optimize the HIV care continuum for adults and adolescents, including enhancing the care environment, addressing contextual barriers to scaling up services, and measuring and monitoring the HIV care continuum.

The target audience for these guidelines includes care providers, program managers, policymakers, affected communities, organizations, and health systems involved with implementing HIV programs and/or delivering HIV care.

## Guidelines Methodology, Process, and Structure

A systematic search of the US Centers for Disease Control and Prevention (CDC) Research Project Database was conducted to identify randomized controlled trials (RCTs), observational studies with or without comparators, as well as cross-sectional and descriptive studies from January 2002 to July 2013. The CDC Research Project Database draws literature from bibliographic databases such as MEDLINE, CINAHL, PsycINFO, and EMBASE. Additional scientific input included hand reviews of RCTs, observational studies, and modeling papers focused on the HIV care continuum. A total of 6132 articles met the criteria (6020 within the review's time frame augmented by an additional 121 more recent articles reporting on studies deemed to be of sufficient scientific merit and programmatic importance to be included in the evidence base). Data were extracted and coded by 6 independent reviewers using standardized data extraction forms.

Based on the advisory panel's analyses of the available data, an evidence base comprising 1047 articles was used to support the development of evidence-based recommendations by advisory panel members. The evidence base is comprised of 131 RCTs, 171 observational studies, and 745 other data sources, including guidelines, systematic reviews, and descriptive articles. Recommendations were graded based on the quality of evidence, and this informed the strength given to each recommendation. Table 1 summarizes the grading scales used. Additional details regarding the methodology used to formulate the recommendations are available as Supplemental Appendix 1.

The guidelines are structured in 6 sections, each containing graded recommendation statements. Table 2 lists the 36 recommendation statements. Supporting statements are provided for each recommendation. The supporting statements include selected articles from within the evidence base that provide context to and/or explain the basis for the recommendations.

In most instances, the evidence supporting the recommendations is generalizable across populations and settings. Nonetheless, the advisory panel notes that in relation to some recommendations, there is a challenge of context because implementation of a recommendation may be uniquely demonstrated in one setting but may not transfer well in another. In such instances, there is a need to measure both performance and outcomes as recommendations are implemented to ensure

**Table 1.** Grading Scales for Strength of Recommendation and Quality of the Body of Evidence.

Strength of the Recommendation	Interpretation
Strong (A)	Almost all patients should receive the recommended course of action.
Moderate (B)	Most patients should receive the recommended course of action. However, other choices may be appropriate for some patients.
Optional (C)	There may be consideration for this recommendation based on individual patient circumstances. Not recommended routinely.
Quality of the Body of Evidence	Interpretation
Excellent (I)	RCT evidence without important limitations; overwhelming evidence from observational studies
High (II)	RCT evidence with important limitations; strong evidence from observational studies
Medium (III)	RCT evidence with critical limitations; observational study without important limitations
Low (IV)	Other evidence, including extrapolations from bench research, usual practice, expert opinion, consensus guidelines; observational study evidence with important or critical limitations

Abbreviation: RCT, randomized controlled trial.

that there are not unique features related to the population or the setting that could affect the outcomes.

Table 3 provides context to and describes recommended standards for measurement of the HIV care continuum. While outside the scope of these guidelines, the advisory panel also developed guidance on a series of issues specific to key populations that are disproportionately affected by HIV/AIDS, which is available as Table 4. Finally, the advisory panel identified gaps in the available data regarding the HIV care continuum, which are the basis for future research recommendations listed in Table 5.

## Guidelines

### Optimizing the HIV Care Environment

In many settings, optimizing the HIV care environment may be the most important action to ensure that there are meaningful increases in the number of people who are tested for HIV, linked to care, started on ART if diagnosed to be HIV positive, and assisted to achieve and maintain long-term viral suppression.<sup>13–15</sup> Overcoming the legal, social, environmental, and structural barriers that limit access to the full range of services across the HIV care continuum requires multistakeholder engagement, diversified and inclusive strategies, and

**Table 2.** Evidence-Based Recommendations for Optimizing the HIV Care Continuum.**Optimizing the HIV care environment**

1. Laws that criminalize the conduct of or exert punitive legal measures against MSM, transgender individuals, substance users, and sex workers are not recommended and should be repealed where they have been enacted. (A IV)
2. Laws that criminalize the conduct of PLHIV based on perceived exposure to HIV, and without any evidence of intent to do harm, are not recommended and should be repealed where they have been enacted. (A IV)
3. HIV-related restrictions on entry, stay, and residence in any country for PLHIV are not recommended and should be repealed where they have been enacted. (A IV)
4. Strategies to monitor for and eliminate stigma and discrimination based on race, ethnicity, gender, age, sexual orientation, and/or behavior in all settings, but particularly in health care settings, using standardized measures and evidence-based approaches, are recommended. (B II)
5. Proactive steps are recommended to identify and manage clinical mental health disorders (eg, anxiety, depression, and traumatic stress) and/or mental health issues related to HIV diagnosis, disclosure of HIV status, and/or HIV treatment. (A II)
6. Enabling PLHIV to take responsibility for their care (eg, self-management, user-driven care) is recommended. (B I)
7. Shifting and sharing HIV testing, dispensing of ART, and other appropriate tasks among professional and paraprofessional health worker cadres is recommended. (A I)
  - 7a. Use of lay health workers to provide pretest education and testing and to enhance PLHIV engagement in HIV care is recommended. (B I)
  - 7b. Task shifting/sharing from physicians to appropriately trained health care providers, including nurses and associate clinicians, is recommended for ART initiation and maintenance. (B II)
8. Community engagement in every step across the HIV care continuum is recommended. (B II)

**Increasing HIV testing coverage and linkage to care**

9. Routinely offering opt-out HIV testing to all individuals who present at health facilities is recommended. (A I)
10. Community-based HIV testing is recommended to reach those who are less likely to attend facility-based HIV testing. (A I)
11. Confidential, voluntary HIV testing in large workplace and institutional settings (military, police, mining/trucking companies, and educational venues) should be considered. (B III)
12. HIV self-testing is recommended with the provision of guidance about the proper method for administering the test and direction on what to do once the results have been obtained. (B II)
13. Use of epidemiological data and network analyses to identify individuals at risk of HIV infection for HIV testing is recommended. (B II)
14. The offer of HIV testing to partners of newly diagnosed individuals is recommended. (A I)
15. Immediate referral to HIV care is recommended following an HIV-positive diagnosis to improve linkage to ART. (A I)
16. For high-risk individuals who test HIV negative, offering PrEP is recommended in addition to the provision of free condoms, education about risk reduction strategies, PEP, and voluntary medical male circumcision. (A I)
17. Use of case managers and patient navigators to increase linkage to care is recommended. (B II)

**Increasing HIV treatment coverage**

18. The immediate offer of ART after HIV diagnosis, irrespective of CD4 count or clinical stage, is recommended. (A I)
19. First-line ARV regimens with the highest levels of efficacy, lowest adverse event profiles, and delivered in QD fixed-dose combinations are recommended. (B II)
20. Viral load testing at least every 6 months is recommended as the preferred tool for monitoring ART response. (B II)
21. HIV drug resistance testing is recommended at entry into care or prior to ART initiation and when virologic failure is confirmed. (B I)
  - 21a. Where routine access to HIV drug resistance testing is restricted, population-based surveillance is recommended. (B II)
22. Community-located ART distribution is recommended. (A II)
  - 22a. The use of community-based pharmacies should be considered. (C III)

**Increasing retention in care, ART adherence, and viral suppression**

23. Systematic monitoring of retention in HIV care is recommended for all patients. (A II)
  - 23a. Retention in HIV care should be considered as a quality indicator. (B III)
  - 23b. Measuring retention in HIV care using electronic health record and other health system data is recommended. (B II)
  - 23c. Use of clinic databases/surveillance systems for HIV clinical monitoring and population-level tracking is recommended. (B II)
24. Routine ART adherence monitoring is recommended in all patients. (A II)
  - 24a. Viral suppression is recommended as the primary adherence monitoring metric. (B II)
  - 24b. Routine collection of self-reported adherence data from patients is recommended. (A I)
  - 24c. Pharmacy refill data are recommended for adherence monitoring. (B II)
25. Information and communication technologies aimed at supporting patient self-care are recommended. (B II)
  - 25a. Mobile health technology using weekly interactive components (eg, 2-way SMS) is recommended. (B I)
  - 25b. Alarm devices are recommended as reminders for PLHIV with memory impairment. (A I)
26. Patient education about and offering support for medication adherence and keeping clinic appointments are recommended. (A I)
  - 26a. Pillbox organizers are recommended, particularly for HIV-infected adults with lifestyle-related barriers to adherence. (B II)
27. Neither directly administered nor directly observed ART is recommended for routine clinical care settings. (A I)
  - 27a. Directly administered ART is recommended for people who inject drugs and released prisoners at high risk of ART nonadherence. (B I)

(continued)

**Table 2.** (continued)

---

28.	Proactive engagement and reengagement of patients who miss clinic appointments and/or are lost to follow-up, including intensive outreach for those not engaged in care within 1 month of a new HIV diagnosis, is recommended. (B II)
28a.	Case management to retain PLHIV in care and to locate and reengage patients lost to follow-up is recommended. (B II)
28b.	Transportation support for PLHIV to attend their clinic visits is recommended. (B II)
<b>Adolescents</b>	
29.	Removing adult-assisted consent to HIV testing and counseling is recommended for minor adolescents with the capacity to consent. (B II)
30.	Adolescent-centered services are recommended in both clinical and community-based settings. (A IV)
31.	Informing an adolescent of his/her HIV-positive diagnosis is recommended as soon after diagnosis as feasible. (B II)
32.	A transition plan between pediatric and adult HIV care is recommended. (B II)
<b>Metrics for and monitoring of the HIV care continuum</b>	
33.	A standardized method should be used to estimate the total number of PLHIV (diagnosed and undiagnosed) within a geographic setting. (A IV)
34.	The estimated number of PLHIV in the geographic setting should be the overall denominator for the HIV care continuum. (A IV)
35.	Collection of a minimum set of 5 data elements should be considered to populate the HIV care continuum. (A IV)
	<ul style="list-style-type: none"> <li>• Estimated number of PLHIV</li> <li>• Number and proportion of PLHIV who are diagnosed as having HIV</li> <li>• Number and proportion of PLHIV who are linked to care (optional)</li> <li>• Number and proportion of PLHIV on ART</li> <li>• Number and proportion of PLHIV on ART who are virally suppressed</li> </ul>
36.	Where possible, jurisdictions should consider longitudinal cohort measurement of HIV service utilization and treatment outcomes to identify the means to maximize viral suppression through ensuring early access to ART and retention in care. (A IV)

---

Abbreviations: ARV, antiretroviral; ART, antiretroviral therapy; MSM, men who have sex with men; PLHIV, people living with HIV; PEP, postexposure prophylaxis; PrEP, preexposure prophylaxis; QD, once-daily; SMS, short message services.

innovative approaches. Addressing laws that criminalize the conduct of key populations and supporting interventions that reduce HIV-related stigma and discrimination are also critically important. People living with HIV also require support through peer counseling, education, and navigation mechanisms, and their self-management skills reinforced by strengthening HIV literacy across the continuum of care.

**Recommendation 1: Laws that criminalize the conduct of or exert punitive legal measures against men who have sex with men, transgender individuals, substance users, and sex workers are not recommended and should be repealed where they have been enacted. (A IV)**

Many countries have enacted legal measures to make substance use and certain sexual behaviors among consenting adults illegal and have imposed mandatory HIV testing requirements and/or forced rehabilitation for men who have sex with men (MSM), transgender individuals, substance users, and sex workers. Sexual minorities and sex workers often face significant vulnerability to HIV as a result of high-risk behavior (eg, substance use), poor coverage by HIV and health care services, social marginalization, and continuing stigma and discrimination.<sup>16–19</sup> Criminalizing the conduct of sexual minorities exacerbates the stigma and discrimination experienced by these individuals, which may result in increased HIV transmission and acquisition risks and contribute to decreased access to and utilization of HIV services.<sup>20</sup>

**Recommendation 2: Laws that criminalize the conduct of PLHIV based on perceived exposure to**

**HIV, and without any evidence of intent to do harm, are not recommended and should be repealed where they have been enacted. (A IV)**

Numerous countries have enacted laws that criminalize behaviors associated with HIV exposure, many of which pose a low or negligible HIV transmission risk.<sup>21–23</sup> No differences in behavior have been noted between settings that enact such laws and those that do not.<sup>24–28</sup> Many of these laws do not take into account measures that reduce HIV transmissibility, including condom use,<sup>29,30</sup> and were enacted before the preventive benefit of ART<sup>31</sup> or antiretroviral (ARV)-based preexposure prophylaxis (PrEP)<sup>32</sup> was fully characterized. Most PLHIV who know their status take steps to prevent transmitting HIV to others.<sup>33,34</sup> HIV-specific laws thus primarily exacerbate HIV-related stigma and decrease HIV service uptake.<sup>21,35–37</sup>

**Recommendation 3: HIV-related restrictions on entry, stay, and residence in any country for PLHIV are not recommended and should be repealed where they have been enacted. (A IV)**

HIV-related travel restrictions fail to protect public health, run contrary to human rights principles, and may result in deleterious effects on HIV prevention and care. Nonetheless, many countries continue to impose such restrictions for PLHIV. These restrictions increase the stigmatization of migrants and PLHIV, discourage HIV testing, and can exacerbate marginalization by restricting the rights and opportunities of PLHIV.<sup>38,39</sup> Additionally, in humanitarian settings, although refugees are typically eligible for HIV services including ART through human rights laws and agreements, the rights of internally



displaced populations to care are often more precarious.<sup>40</sup> Action is needed to repeal laws restricting travel for migrants living with HIV and to ensure comprehensive access to health care for all PLHIV.

**Recommendation 4: Strategies to monitor for and eliminate stigma and discrimination based on race, ethnicity, gender, age, sexual orientation, and/or behavior in all settings, but particularly in health care settings, using standardized stigma measures and evidence-based approaches are recommended. (B II)**

Stigma can negatively shape quality of life, affect mental health, and influence ART use and outcomes. Studies have shown that individuals on ART face greater stigma and that health care settings and the personal environment were areas where the most stigma was experienced.<sup>41–43</sup> A number of interventions have been shown to reduce HIV/AIDS stigma, including peer-led or -based strategies, community and popular leader interventions,<sup>44</sup> health care provider interventions, and community-level biomedical approaches.<sup>45</sup> The use of standardized stigma measures is recommended to ensure better comparability across health care and epidemic settings.<sup>46,47</sup> The People Living with HIV Stigma Index developed by and for PLHIV is recommended as an instrument that can be adapted and used in different settings.<sup>48</sup>

**Recommendation 5: Proactive steps are recommended to identify and manage clinical mental health disorders (eg, anxiety, depression, and traumatic stress) and/or mental health issues related to HIV diagnosis, disclosure of HIV status, and/or HIV treatment. (A II)**

Clinical mental health disorders such as anxiety, depression, and traumatic stress need to be proactively identified and treated to reduce their severity, as they place individuals at an increased risk of acquiring HIV and of HIV treatment failure. Mental health disorders such as these can result in a poorer quality of life and negatively affect access to and use of HIV services. Interventions in clinical settings can be effective in addressing mental health disorders among PLHIV and improving health outcomes.<sup>50,51</sup> Connecting PLHIV to mental health services at critical points along the HIV care continuum can help identify and treat mental health issues that may arise due to a diagnosis of HIV. It is recommended that measures of mental health be appropriately tailored and comparable across populations in broad categories (eg, different dimensions of emotional well-being).<sup>52,53</sup> Numerous observational studies show a significant adverse effect of comorbid psychiatric conditions on treatment outcomes among substance users, with strong evidence of an adverse effect of depression on ART adherence and treatment outcomes.<sup>54,55</sup> A recent meta-analysis found that treatment for depression increases the odds of ART adherence by 83%.<sup>49</sup>

**Recommendation 6: Enabling PLHIV to take responsibility for their care (eg, self-management, user-driven care) is recommended. (B I)**

Enabling PLHIV to manage their care has several positive health outcomes including improvement in physical and psychological health; improved social relationships with families, communities, and providers; improved health literacy and seeking out HIV support and care services; and improved behavior change such as improved ART adherence.<sup>56–61</sup> An RCT conducted in San Francisco assessing the efficacy of a self-management intervention among HIV-positive adults with high levels of self-reported ART distress showed positive effects for ART adherence and health-seeking behaviors among those randomized to the intervention. Those in the intervention group had a 6% decrease per month in the odds of nonadherence compared to unchanged adherence among the control group, and further, those who received the intervention were more likely to seek out information and social support to cope with side effects.<sup>60</sup> Education about self-management and user-driven techniques can be accomplished through primary care visits, through peer or lay health worker-led interventions, and by the use of mobile phones or the Internet to self-monitor and manage health.<sup>57,62–66</sup>

**Recommendation 7: Shifting and sharing HIV testing, dispensing of ART, and other appropriate tasks among professional and paraprofessional health worker cadres is recommended. (A I)**

- **7a. Use of lay health workers to provide pretest education and testing and to enhance PLHIV engagement in HIV care is recommended. (B I)**
- **7b. Task shifting/sharing from physicians to appropriately trained health care providers, including nurses and associate clinicians, is recommended for ART initiation and maintenance. (B II)**

When provided with appropriate training and oversight and when guided by national policies, lay health workers can effectively distribute ART, provide pretest education and testing, and support related administrative tasks at the facility and community levels. Task shifting has been shown to be cost-effective<sup>67</sup> and allows for significantly increased patient enrollment<sup>68</sup> while maintaining quality of care<sup>69,70</sup> and retention in care<sup>71</sup> as well as improving ART adherence.<sup>72</sup> Use of community-based outreach workers or peers of similar risk status/cultural backgrounds has been shown to improve the uptake of HIV testing within social and risk-based networks when provided appropriate preservice and in-service training and competent professionally based supervision.<sup>73,74</sup> Additionally, community-based HIV rapid testing attracts those who are unlikely to undergo routine HIV testing at a medical facility, such as people from key populations affected by HIV or people who are working during clinic hours.<sup>44,75</sup> Multi-disease prevention campaigns have been used to increase

participation and access to HIV testing by providing multiple health interventions that have a broader appeal.<sup>76</sup> Satisfaction with the services among clients was high in 1 study, with 92% reported being “very satisfied.”<sup>77</sup> Counseling by community-based counselors increased uptake in pre-ART care,<sup>78</sup> decreased virologic failure,<sup>79</sup> and improved ART adherence and CD4 count response.<sup>80,81</sup> Nurse-led interventions were linked to improved ART adherence,<sup>82</sup> a significantly higher rate of retention in care,<sup>83</sup> and a decreased number of patients lost to follow-up.<sup>81,84</sup>

**Recommendation 8: Community engagement in every step across the HIV care continuum is recommended. (B II)**

Models of community-based support and ART delivery to complement facility-based ART programs can be effective strategies for enhancing psychosocial support and improving access to and outcomes across the HIV care continuum.<sup>71,85–90</sup> The involvement of patients in chronic disease management in high-income countries has often resulted in improved health outcomes and increased utilization of health services. There is also evidence from low-income, high HIV burden countries that people living with chronic diseases can be trained to effectively act as tutors or peer navigators for other patients, particularly in settings with a severe shortage of human resources for health.<sup>91–94</sup> The cost-effectiveness and potential relevance of this approach in countries with a high HIV burden have been documented.<sup>84–87</sup>

**Increasing HIV Testing Coverage and Linkage to Care**

Optimizing the offer of HIV testing (“seek and test”) is the critical first step in addressing the HIV care continuum. This should be done within the context of a high-quality confidential diagnosis in the location that best suits the individual’s needs. A critical focus should be placed on posttest counseling and immediate linkage to care for those found to be HIV positive as well as immediate access to ART.<sup>95</sup> The Strategic Timing of AntiRetroviral Treatment (START) study recently showed a 53% reduction in serious morbidity and mortality from HIV due to early ART at CD4 counts of over 500 cells/mm<sup>3</sup> compared to deferred initiation of ART at CD4 counts of 350 cells/mm<sup>3</sup>.<sup>96</sup> Health care systems should strive to make HIV screening widely available and accessible to all individuals regardless of gender, age, or perceived risk factors.<sup>97</sup> In addition, targeted HIV testing approaches are recommended both in concentrated and in generalized epidemics.

Linkage to medical care is a critical but often neglected step in the HIV care continuum.<sup>98</sup> It can be defined as the process that facilitates a newly diagnosed person’s optimal engagement in HIV care. Typically, linkage may consist of verbal or written referral to an HIV care facility by the counselor or the individual who provided the HIV test result.<sup>99</sup> In settings where HIV testing and care are provided at the same or a nearby facility,

recently diagnosed persons may be escorted from the test site to the care site to ensure that this initial linkage is successful. Other programs use “navigators” to ensure linkage to services that may not be available at the same site and/or provided on the same day.<sup>100,101</sup>

Linkage to care should enable a patient living with HIV to engage in care early, benefit from a broad package of care, and facilitate immediate access to ART. Prompt engagement in HIV care also optimizes individual and public health outcomes.<sup>31</sup> Linkage to care is attenuated by economic, geographic, transportation, and distance barriers, as well as stigma and discrimination,<sup>102,103</sup> all of which should be addressed in efforts to optimize the HIV care environment.

**Recommendation 9: Routinely offering opt-out HIV testing to all individuals who present at health facilities is recommended. (A I)**

Routine HIV screening identifies significantly more undiagnosed HIV infections than a risk-based approach, and routine screening is generally cost-effective in populations that meet minimum thresholds of HIV prevalence of >0.1%.<sup>97</sup> Opt-out HIV screening and testing means that the patient is notified orally or in writing that an HIV test will be performed unless the patient declines. Opt-out testing is now routinely recommended in both national and international guidelines, with the provision of pretest information about the meanings of positive and negative test results made available within the cultural context in the languages of the populations encountered within the area in which testing is being offered.<sup>97,104</sup> In a retrospective cohort study, 2408 (73%) of 3303 HIV-infected women diagnosed during the study period had missed-opportunity medical visits, suggesting that a routine offer could have diagnosed them earlier.<sup>105</sup> Another retrospective cohort study indicated that the 1769 individuals diagnosed “late” with HIV (ie, who developed AIDS within 1 year of their diagnosis) made a total of 7988 visits to a health facility during 1997 to 2005 before their first reported positive HIV test.<sup>106</sup> Further, the diagnoses reported that nearly 8 in 10 of these visits were not likely to prompt HIV testing under a risk-based testing strategy. Opt-out HIV testing has been demonstrated to increase HIV testing coverage and aid in earlier detection of the virus.<sup>107,108</sup> In addition to general medical/primary care outpatient settings, this recommendation includes outpatient venues where individuals seek care for conditions associated with HIV, such as tuberculosis (TB), viral hepatitis, and sexually transmitted infection (STI).

**Recommendation 10: Community-based HIV testing is recommended to reach those who are less likely to attend facility-based HIV testing. (A I)**

One RCT,<sup>109</sup> a systematic review and meta-analysis,<sup>110</sup> and numerous observational studies examined various community-based testing approaches.<sup>111–117</sup> In addition to routine HIV screening in facility-based settings, community-based HIV testing approaches have the potential to normalize testing

within a community and among couples to significantly expand HIV testing and to reach those who do not access the health system. Project Accept (HPTN 043) was especially effective in reaching men<sup>109</sup> and also demonstrated a 4-fold increase in identifying previously undiagnosed HIV cases in comparison to the control group. Community-based HIV testing interventions<sup>118</sup> identified a larger proportion of people who had tested for the first time and who had CD4 counts above 350 cells/mm<sup>3</sup> than standard facility-based HIV testing, though the positivity rate was lower. Overall acceptability of the approaches exceeded 80%.<sup>118</sup> Using varied modalities to reach people<sup>119,120</sup> has the potential to reach those who have never been tested before. Multidisease prevention community health campaigns that combine other public health interventions<sup>121</sup> with HIV testing and counseling, such as maternal-child health programs, can be effective<sup>122</sup> and cost-efficient.<sup>123,124</sup> Community-based HIV testing of individuals and couples should be coupled with follow-up by an HIV-positive patient navigator. Such an intervention can significantly contribute to linking and retaining HIV-positive persons to care in a timely manner.<sup>125</sup>

**Recommendation 11: Confidential, voluntary HIV testing in large workplace and institutional settings (military, police, mining/trucking companies, and educational venues) should be considered. (B III)**

HIV prevalence is often higher than anticipated or reported among employee populations in large institutional settings, particularly in communities where the undiagnosed HIV seroprevalence is >0.1%.<sup>126–128</sup> Screening programs for individuals and for couples in such settings have the potential to identify undiagnosed individuals earlier than they might otherwise present (ie, if they waited until they were symptomatic) and get them early into care, so that they can optimize their own health by starting ART and protect their partners. However, stigma and confidentiality concerns remain significant barriers to acceptance of HIV testing in some workplace settings, especially in communities where stigma due to HIV is acute (eg, mining/trucking companies).<sup>129–131</sup> In such communities, voluntary workplace testing should be conducted after strict implementation of confidentiality measures and assurances of fair treatment of those who test HIV positive. Despite high acceptance of the HIV test offer at employment sites, some studies have suggested that follow-up rates can be low and that HIV positivity can be a risk factor for nonattendance at follow-up.<sup>129</sup> These results point to the likely benefit of rapid test results in employee testing programs, as well as supportive and rapid linkage to care protocols. Although the near-term individual and public health benefits of knowing one's HIV status may be clear, it is important for patients and providers to consider the context and prevent the negative aspects of stigma and criminalization. Thus, testing interventions in workplaces and institutional settings are advisable only in high-prevalence situations and where the dangerous consequences of stigma, employment impact, and criminalization can be managed.

**Recommendation 12: HIV self-testing is recommended with the provision of guidance about the proper method for administering the test and direction on what to do once the results have been obtained. (B II)**

HIV self-testing can happen in private with indirect support such as provision of referral information or can be supervised with moderate pretest and/or posttest support. The modality can include nonrestricted access to HIV self-testing through various sites and locations (eg, over the counter, vending machines, pharmacies, and the Internet) or through community or health care facility distribution. Three cross-sectional feasibility studies<sup>132–134</sup> examined the acceptability and uptake of HIV self-testing in different settings for different populations. All the studies reviewed demonstrated that the testing modality is well accepted in both high-prevalence settings and concentrated epidemics, and across different populations,<sup>133–135</sup> with high accuracy after moderate direction on how to use the self-test which should include instruction on confirming preliminary positive results and linkage to care if confirmed positive. HIV self-testing was also cost-effective in resource-limited settings.<sup>136</sup> Ensuring high-quality products for self-testing through regulatory processes and policies concerning medical devices and regulating the legal use of the devices are essential for scale-up of quality HIV self-testing.

**Recommendation 13: Use of epidemiological data and network analyses to identify individuals at risk of HIV infection for HIV testing is recommended. (B II)**

Use of epidemiological data to guide HIV testing has been a key component of HIV testing practices since the beginning of the epidemic. Use of network analysis has been instrumental in understanding the transmission dynamics of HIV among MSM.<sup>137</sup> Offering HIV testing to members of networks identified to be at risk for further HIV transmission is recommended. A systematic review of studies of partner notification and referral for HIV testing found that this strategy identified an HIV seropositivity rate of 1% to 8% among partners of an index case.<sup>138</sup> Use of network analysis has led to enhanced HIV testing among vulnerable populations, including black MSM.<sup>139,140</sup> Network-based peer recruitment for HIV testing led to improved HIV testing rates within networks (sexual and in injection drug users) in the United States, with a subsequent HIV seroprevalence rate of 5% among those tested.<sup>141</sup>

**Recommendation 14: The offer of HIV testing to partners of newly diagnosed individuals is recommended. (A I)**

Public health interventions for the follow-up of persons newly diagnosed with HIV, such as partner services and short-term case management, are strongly recommended. Partners and other contacts who may be infected with HIV should be notified and offered testing. All newly diagnosed individuals



should be helped to link to HIV primary care. Voluntary partner notification should be considered, being mindful of stigma concerns and criminalization-related issues in jurisdictions where this is relevant. A systematic review<sup>138</sup> found that 67% of the partners identified were notified, with 63% undergoing HIV testing with a mean HIV diagnosis rate of 20%. Another study found that provider notification was higher than self-notification (51% versus 24% for self-notification).<sup>142</sup> Partner- or couple-based HIV testing and counseling can be more supportive and can facilitate safe disclosure, and it is therefore recommended that health care providers consider initiating such discussions with women and with men and their partners. Knowing that a partner has taken an HIV test and knowing a partner's HIV status are associated with HIV testing among pregnant women.<sup>143</sup> HIV-positive pregnant women whose partners have an unknown HIV serostatus are more likely to be lost to follow-up.<sup>144</sup>

**Recommendation 15: Immediate referral to HIV care is recommended following an HIV-positive diagnosis to improve linkage to ART. (A I)**

A study involving 1928 patients in New York City showed that initiation of HIV care was more likely to occur when HIV testing was conducted at a clinical site with access to HIV care.<sup>145</sup> In Uganda, outpatients referred to HIV testing (74%) were more likely to attend an HIV clinic within 6 months than those receiving HIV testing and counseling on-site as inpatients.<sup>146</sup> In another study conducted in a hospital emergency department, on-site linkage teams were able to connect more than 90% of newly diagnosed and out-of-care HIV-infected patients to HIV care services.<sup>147</sup> However, in other hospital settings, suboptimal ART eligibility assessments and referral systems created unnecessary delays and attrition in the pre-ART clinical management period.<sup>148</sup>

**Recommendation 16: For high-risk individuals who test HIV negative, offering PrEP is recommended in addition to the provision of free condoms, education about risk reduction strategies, postexposure prophylaxis (PEP), and voluntary medical male circumcision. (A I)**

The use of ART and PrEP reduces the transmission risk to 0.5% among adherent HIV-uninfected individuals who are serodiscordant couples.<sup>149</sup> HIV serodiscordance in couples is common, and approximately 45% of HIV-infected individuals have an HIV-negative partner.<sup>150</sup> The option of early ART in combination with PrEP while the index member of the couple has a detectable viral load should be considered among HIV-serodiscordant monogamous couples, as a means to virtually eliminating the likelihood of HIV transmission. In an open-label trial of daily PrEP in high-risk MSM, an 86% reduction in the risk of HIV infection was observed in the PrEP treatment group compared to no PrEP, and the number needed to treat to prevent a single infection was 13.<sup>32</sup> It bears noting that PrEP is one of many prevention options for people who are not infected

with HIV. Condoms, like most other HIV prevention interventions, are effective when used correctly and consistently and have been shown to reduce heterosexual HIV transmission by 80%.<sup>151</sup> Within the context of PrEP, condoms protect against STIs not prevented by PrEP, thus regular monitoring and counseling regarding condom use are advised given recent data from PrEP use in regular clinical practice in San Francisco indicating a 40% drop-off rate in condom use among PrEP users.<sup>152</sup> Voluntary male medical circumcision has been proven to be effective in 3 RCTs which demonstrated around a 60% reduction in transmission risk for circumcised heterosexual men.<sup>153–155</sup> Postexposure prophylaxis, by blocking HIV infection, is recommended for people who had occupational exposure such as needle stick (after careful evaluation of the circumstances) and after sexual assault.<sup>156</sup> For persons who inject drugs, opioid substitution treatment and needle and syringe programs are recommended as part of an evidence-based harm reduction package.<sup>157–160</sup>

**Recommendation 17: Use of case managers and patient navigators to increase linkage to care is recommended. (B II)**

Case management is a collaborative process of assessment, planning, facilitation, care coordination, evaluation, and advocacy for options and services to meet a patient's health needs and achieve health, quality, cost-effectiveness, and outcomes. Case managers have been successfully used to strengthen patient outcomes throughout the HIV care continuum including early linkage to care, retention in care, and sustained ART adherence.<sup>161–163</sup> Additionally, case managers have been demonstrated to be useful in reaching hard-to-reach and key populations.<sup>162</sup> Patient navigators are individuals who assist individual patients to navigate through the continuum of care as it pertains to the patient's specific disease, ensuring that barriers to that care are resolved and that each stage of care is as seamless as possible. The benefit provided by patient navigators in relation to linkage to care is also well documented.<sup>98,164,165</sup> Newly diagnosed HIV-positive persons have been more successfully linked to care when supported or encouraged by a patient navigator.<sup>166</sup> When the patient navigator is also a person living with HIV, the potential magnitude of benefit may be even higher.<sup>103</sup>

### *Increasing HIV Treatment Coverage*

Increasing early access to ART is associated with decreased AIDS-related morbidity and mortality, as well as reduced risk of HIV transmission.<sup>167</sup> Final results of the HPTN 052 clinical trial showed a 72% risk reduction in HIV transmission among 1763 serodiscordant couples with immediate initiation of ART.<sup>168</sup> Importantly, no genetically linked HIV transmissions occurred when the index member of the couple had an undetectable viral load. Preliminary results from the PARTNERS study of 1100 serodiscordant couples, 40% of them were MSM, found that there had been no HIV transmission within couples who were not using condoms from a partner with an



undetectable viral load, albeit with large confidence intervals around this estimate.<sup>169</sup>

Recently, final results of 2 major RCTs provided strong evidence of the benefit of early ART initiation. The TEMPRANO study showed that initiating ART at the 500 cells/mm<sup>3</sup> threshold in lower-income settings with a high prevalence of TB and bacterial infections reduced the risk of serious illness, including TB and death, by 44% when compared to starting ART according to 2013 WHO guidance.<sup>170</sup> Similarly, as noted previously, the START study showed that among 4685 patients in 35 nations, the risk of progression to AIDS, other serious illnesses, or death was reduced by 53% among people who initiated treatment immediately.<sup>96</sup> The START study results are especially important because the magnitude of the health benefit conferred by ART was similar in high- and low-income countries.

**Recommendation 18: The immediate offer of ART after HIV diagnosis, irrespective of CD4 count or clinical stage, is recommended. (A I)**

The benefits of ART, such as prevention of illness, death, and transmission, extend to persons irrespective of CD4 count, including those with recent or long-standing HIV infection and/or those with normal to severely depleted CD4 counts.<sup>95,110</sup> Antiretroviral therapy initiation should not be delayed in individuals with acute opportunistic infections, including TB or *Pneumocystis pneumonia*, with the notable exception of cryptococcal meningitis and other opportunistic infections associated with increased intracranial pressure.<sup>171</sup> HIV is the strongest known risk factor for developing TB, and ART is the strongest TB prevention intervention for PLHIV.<sup>110</sup> In one large randomized trial, initiation of ART during TB therapy resulted in a 56% reduction in death, and this result was observed in all CD4 count strata.<sup>172</sup> Antiretroviral therapy should be provided as soon as possible after a diagnosis of HIV infection and no later than 8 weeks after initiating TB treatment. For those individuals with severe immunosuppression and TB, ART should be offered within 2 weeks of initiating TB treatment. The use of ART to prevent HIV transmission to sexual partners as well as from mother to child (through Option B+) may be an added incentive for starting immediate life-long ART.<sup>173</sup> In resource-limited settings, programmatic prioritization of vulnerable groups of people should be considered to ensure that they get access to treatment. CD4 count monitoring is optional for individuals who are on stable ART and who have been virologically suppressed for more than 2 years.<sup>174,175</sup> If available, assessment of CD4 count is recommended to direct prevention of opportunistic infections. However, the initiation of ART for prophylaxis against opportunistic infections should not be denied or deferred if CD4 count testing is not available.

**Recommendation 19: First-line ARV regimens with the highest levels of efficacy, lowest adverse event profiles, and delivered in once-daily (QD) fixed-dose combinations are recommended. (B II)**

Antiretroviral therapy is proven to prevent HIV-related morbidity, mortality, and transmission.<sup>7</sup> Immediate initiation of ART maximizes the opportunity to achieve these objectives. The thoughtful selection of ART and the maintenance of patients on first-line treatment are therefore central to care for PLHIV. A number of highly effective, well-tolerated, QD-dosed, first-line ARV regimen options are available, including nonnucleoside reverse transcriptase (NNRTI)-, ritonavir (RTV)-boosted protease inhibitor (PI)-, and integrase inhibitor-based regimens. For example, recent RCTs using integrase inhibitor-based ARV regimens for first-line ART have demonstrated statistical superiority or comparability to other commonly recommended regimens.<sup>176–179</sup> Study superiority was driven by improved tolerability and lower adverse event profiles of these integrase inhibitor-based ARV regimens. Whenever possible, switching ARV regimens following evidence-based strategies to address adverse effects, toxicity, or advances in medications (eg, increased efficacy) should be considered.<sup>180,181</sup> Fixed-dose combinations are preferred to aid with ART adherence and decrease risks during medication stock-outs.<sup>182</sup> Patients taking QD-dosed regimens have higher rates of adherence than those taking twice-daily dosed regimens.<sup>182</sup> Although challenging within the context of HIV care delivered via a public health approach in resource-limited settings, care should nevertheless be taken to individualize treatments based on transmitted drug resistance, comorbid illness, and/or lifestyle considerations.

**Recommendation 20: Viral load testing at least every 6 months is recommended as the preferred tool for monitoring ART response. (B II)**

Suppression of viral replication is the key therapeutic goal as it is the driver of individual and public health outcomes. Measuring plasma HIV-1 RNA levels through a viral load test is the preferred laboratory tool for HIV disease prognosis and to guide HIV treatment strategies. Viral load testing should be used after ART initiation as a means to monitor ART response.<sup>183</sup> However, lack of availability of viral load testing should not delay the initiation of ART. A patient's HIV-1 RNA level should reach below the limit of quantitation within 6 months of ART initiation. Among individuals who are on stable ART with a CD4 count >350 cells/mm<sup>3</sup> and who have been virologically suppressed for 2 years, viral load monitoring can be performed every 6 to 12 months.<sup>183,184</sup> CD4 counts can be used to help determine eligibility for opportunistic infection prophylaxis but are not effective for assessing ART effectiveness since CD4 count and viral load levels can be discordant.

**Recommendation 21: HIV drug resistance testing is recommended at entry into care or prior to ART initiation and when virologic failure is confirmed. (B I)**

- **21a. Where routine access to HIV drug resistance testing is restricted, population-based surveillance is recommended. (B II)**

Transmitted or treatment-emergent HIV drug resistance may limit the response to ART. Transmitted drug resistance is well documented in both resource-rich and resource-limited settings.<sup>185,186</sup> Transmitted drug-resistant HIV is associated with reduced rates of viral suppression to first-line treatments<sup>187</sup> and occurs in approximately 5% to 15% of treatment-naïve individuals.<sup>188,189</sup> For this reason, where available, HIV drug resistance testing is recommended at entry into care or prior to ART initiation to help guide ARV regimen selection. Treatment-emergent resistance is a major determinant of virologic failure.<sup>190,191</sup> The use of resistance testing in this setting has been shown to improve clinical response to subsequent lines of ART.<sup>192</sup> Resistance testing for an individual is recommended in contexts where there is availability of second- and third-line medicines.<sup>193</sup> In settings where most people do not have access to ART and/or there is limited access to viral load testing, it is advisable to expand access to these interventions while preparing for the medium- and long-term goal of improving access to resistance testing and alternative ART regimens for individual patients before and while they are on ART.<sup>172</sup> In resource-limited settings where individual pre-ART resistance testing is not routinely available, regular population-based surveillance of transmitted resistance in the country is recommended in order to provide information for policy and programmatic considerations. Population-based resistance surveillance can provide important information for decision making about the selection of initial and subsequent ART regimens, the population-level efficacy of ART regimens, as well as PrEP and PEP.<sup>173,194</sup>

**Recommendation 22: Community-located ART distribution is recommended. (A II)**

- **22a. The use of community-based pharmacies should be considered. (C III)**

Community-located ART distribution is a cost-effective service delivery model whose rates of attrition and mortality are similar to those at the facility level.<sup>195,196</sup> A retrospective cohort study in the Bronx, New York, found that HIV services incorporated into community-located primary care setting improved the distribution and delivery of HIV treatment, demonstrated comparable treatment outcomes when compared with a hospital-based specialty center, and achieved slightly lower prevalence of AIDS (46% versus 54%, respectively) in the community-located program.<sup>196</sup> Studies have demonstrated the efficacy of community-based approaches to expanding other HIV services, including testing.<sup>197–199</sup> Community-based ART distribution may also be more effective in helping to retain patients. In Mozambique, Médecins Sans Frontières (MSF) developed a community-located ART adherence and distribution program, now adopted as national policy, which resulted in 91.8% adult retention and 94% youth retention rates at 4 years and facilitated the increased involvement of affected communities in HIV services.<sup>200</sup> Patients receiving specialized ART counseling at community-based pharmacies in multiple US states<sup>201</sup> had significantly

higher ART adherence rates than those using traditional pharmacies.<sup>202</sup> A cohort study in California demonstrated that pharmacist-provided therapy management services were associated with higher ART adherence rates.<sup>203</sup> A pharmacist-managed adherence clinic in Colorado was shown to significantly increase ART adherence rates.<sup>202</sup> In Uganda, ART distribution at community-based sites was found to be associated with significantly higher rates of retention in care and lower mortality rates.<sup>88,204</sup>

**Increasing Retention in Care, ART Adherence, and Viral Suppression**

A number of barriers to HIV treatment engagement are common across countries, even when the availability of local resources may differ widely. Yet, the need to efficiently keep people engaged in their care is more critical than ever, as resources are ultimately limited in every setting, and growing numbers of PLHIV require lifelong care and treatment to attain the individual, public, and community health benefits of early ART.

Significant attrition from HIV care programs has been documented in many settings. Monitoring and optimizing retention in care should be a priority of programs if control of the HIV epidemic and optimal individual health outcomes are to be achieved. Moreover, as life expectancy for PLHIV increases, the impact of successful engagement and retention in care is magnified.

Ultimately, adherence to virologically active ART has been shown to be a major predictor of suppression of HIV replication,<sup>205–207</sup> emergence of drug resistance,<sup>208–210</sup> disease progression,<sup>211</sup> and AIDS-related death.<sup>212–214</sup> The dramatic dose–response pattern between adherence and viral suppression, as well as the reasonable rates of suppression achieved at moderate levels of adherence, supports the recommendation to treat all eligible PLHIV and encourage maximum adherence with each patient.<sup>11,215,216</sup>

**Recommendation 23: Systematic monitoring of retention in HIV care is recommended for all patients. (A II)**

- **23a. Retention in HIV care should be considered as a quality indicator. (B III)**
- **23b. Measuring retention using electronic health record and other health system data is recommended. (B II)**
- **23c. Use of clinic databases/surveillance systems for HIV clinical monitoring and population-level tracking is recommended. (B II)**

Tracking the retention of clients in HIV care is important for the purposes of both clinical and health services and could be considered a part of quality-of-care indicators at both clinic- and surveillance-system levels.<sup>217</sup> Retention measures used and the desired frequency of visits may vary according to jurisdictions and programs, but in order to facilitate effective monitoring, efforts should be made to harmonize measures

with existing national and international recommendations. Gaps in care, visit adherence, and intervals of time between visits, in addition to the use of data including medical records and surveillance systems, are well-tested measures that can be integrated into local standards of HIV care.<sup>218–221</sup> For example, an integrated public health surveillance approach and an electronic health record system in Louisiana were successfully used to provide alerts to medical providers when their clients had been out of HIV care for longer than 12 months.<sup>222</sup> Identifying optimal thresholds of being “out of care” or lost to follow-up remains important, and a 12-week delay in visit, based on pharmacy registry data in South Africa, was considered optimal.<sup>223</sup> Pharmacy tracking data can also include failure to refill medication prescriptions<sup>224,225</sup> and interruptions in laboratory monitoring<sup>226</sup> as warning signs of loss to follow-up (LTFU).

**Recommendation 24: Routine ART adherence monitoring is recommended in all patients. (A II)**

- **24a. Viral suppression is recommended as the primary adherence monitoring metric. (B II)**
- **24b. Routine collection of self-reported adherence data from patients is recommended. (A II)**
- **24c. Pharmacy refill data are recommended for adherence monitoring. (B II)**

Adherence to ART is a reliable predictor of adherence to clinic visits and can be tracked using clinical, immunological, as well as pharmacy and clinic visit measures. Viral load suppression is the most reliable indicator of ART adherence. Viral load surveillance data can be successfully used to monitor engagement and retention in care and improve linkage and retention efforts in local communities.<sup>217</sup> Patient self-report is the most widely used method for evaluating medication adherence,<sup>227</sup> particularly because physician estimates of their patients’ ART adherence is not an effective measure, and evidence shows a poor correlation between physician estimates and patient self-report.<sup>228–230</sup> However, a literature review indicated that pharmacy refill data may be a better measure than self-reported adherence.<sup>231</sup>

**Recommendation 25: Information and communication technologies aimed at supporting patient self-care are recommended. (B II)**

- **25a. Mobile health technology using weekly interactive components (eg, 2-way short message service [SMS]) is recommended. (B I)**
- **25b. Alarm devices are recommended as reminders for PLHIV with memory impairment. (A I)**

The availability and reach of mobile communication have increased worldwide, including in sub-Saharan Africa, where two-thirds of PLHIV reside. A systematic review found that technology-based approaches supporting self-care among PLHIV may improve adherence to ART, especially when these approaches utilized multiple components and facilitated

communication with health care providers.<sup>232</sup> Once-a-week text message or SMS reminders may be the optimal periodicity.<sup>233</sup> There is evidence<sup>233–236</sup> that weekly 2-way SMS improves adherence and virological outcomes in HIV-infected adults in Kenya. Evidence from 2 RCTs<sup>237,238</sup> shows that there is no significant impact of using an alarm on poor adherence or viral failure, except in PLHIV with memory impairment. In fact, appointment reminders alone were found to be useful in a small RCT<sup>239</sup> but only among nonhomeless, nondepressed clients in a much larger RCT.<sup>240</sup>

**Recommendation 26: Patient education about and offering support for medication adherence and keeping clinic appointments are recommended. (A I)**

- **26a. Pillbox organizers are recommended, particularly for HIV-infected adults with lifestyle-related barriers to adherence. (B II)**

Evidence from several RCTs<sup>237,241–243</sup> found that PLHIV who had received targeted adherence counseling were significantly more likely to have optimal adherence and virologic suppression.<sup>227,244,245</sup> Educating patients on the importance of keeping clinic appointments has demonstrated positive effects on retention in care and ART adherence.<sup>246,247</sup> A study assessing the efficacy of an intervention using targeted messages enforcing the importance of regular clinic visits using posters, messages, and brochures in clinics demonstrated a 7% improvement in patients keeping 2 consecutive clinic visits in the intervention year compared to the preintervention year.<sup>247</sup> The use of pillbox organizers has also been associated with improved ART adherence and virologic suppression in patients from difficult-to-treat populations. A study using marginal structural models to estimate the pillbox organizer effect on adherence, viral suppression, and disease progression among a homeless HIV-positive population in the United States found that pillbox organizers were associated with improved adherence, reduction in viral load, and decreased risk of progression to clinical AIDS.<sup>248</sup>

**Recommendation 27: Neither directly administered nor directly observed ART is recommended for routine clinical care settings. (A I)**

- **27a. Directly administered ART is recommended for people who inject drugs (PWID) and released prisoners at high risk of ART nonadherence. (B I)**

Evidence from a meta-analysis of RCTs (N = 12) indicated that directly administered ART did not offer any benefit over self-administered ART.<sup>249</sup> Ten RCTs reported on the primary outcome of virologic suppression for directly observed versus self-administered ART,<sup>249</sup> each reinforcing that this approach is not recommended for supporting ART adherence in a general HIV-infected patient population. Community outreach-based directly administered ART through methadone maintenance treatment programs has been found to be effective in improving



ART adherence and viral suppression among both PWID and released prisoners.<sup>250–253</sup> Its effects decay postintervention, thereby reducing its efficacy in the long term.<sup>254–256</sup> Efficacy is improved markedly when patients are linked to other supportive services.<sup>257</sup>

**Recommendation 28: Proactive engagement and reengagement of patients who miss clinic appointments and/or are lost to follow-up, including intensive outreach for those not engaged in care within 1 month of a new HIV diagnosis, are recommended. (B II)**

- **28a. Case management to retain PLHIV in care and to locate and reengage patients lost to follow-up is recommended. (B II)**
- **28b. Transportation support for PLHIV to attend their clinic visits is recommended. (B II)**

HIV care continuum data from various jurisdictions show that a sizable percentage of those with HIV infection are not engaged in care following an HIV diagnosis, miss clinic appointments, or are lost to follow-up after establishing HIV outpatient care.<sup>15,258–260</sup> In the Antiretroviral Treatment and Access Study (ARTAS) comparing strength-based case management sessions with passive referral to care for patients with recently diagnosed HIV infection, a significantly larger proportion of the case-managed participants visited an HIV clinician at least once within 6 months (78% versus 60%) and at least twice within 12 months (64% versus 49%) using trained linkage case managers to help clients identify their internal strengths and assets to facilitate successful linkage to HIV care.<sup>98</sup> The provision of transportation to the clinic and mental health and drug counseling services to PLHIV who were in need of those services was associated with a 20% improvement in clinic retention.<sup>261,262</sup>

The Retention in Care (RIC) Study conducted with patients at high risk for inadequate retention demonstrated that enhanced personal contact between patients and a trained provider improved retention in care compared to standard contact at the participating clinics.<sup>263,264</sup> This study demonstrated that a low-cost intervention to incorporate retention in care into the clinic culture proved effective in improving visit adherence, particularly among new patients and those with detectable viral loads.<sup>247,264</sup> In addition, a loss to follow-up intervention found that the use of case workers to locate and assist patients to reengage in care was successful in reengaging more than half of those lost to follow-up over an almost 3-year period.<sup>265</sup>

## Adolescents

**Recommendation 29: Removing adult-assisted consent to HIV testing and counseling is recommended in minor adolescents with the capacity to consent. (B II)**

Adolescents are often overlooked in HIV testing and are reluctant to seek out HIV services. Increased awareness

among care providers and policymakers is critical. Provider-initiated testing and the provision of adolescent-friendly testing services outside health facilities are recommended, as is the potential for self-testing.<sup>266</sup> A number of countries require parental consent for HIV testing, which can be a significant barrier to testing.<sup>266</sup> However, nations should consider lowering the age of consent to 12 to 14 years or recognize the evolving capacities of the child in order to give adolescents clear access to HIV counseling and testing. National policies should also acknowledge the holistic nature of HIV counseling and testing and ensure that consent laws do not restrict access to condoms, treatment autonomy, and HIV prevention interventions such as PrEP and medical male circumcision.

**Recommendation 30: Adolescent-centered services are recommended in both clinical and community-based settings. (A IV)**

Youth have repeatedly articulated that engagement with health services should be local, integrated, quick, confidential, nonprejudicial, “hassle-free,” and free (or inexpensive).<sup>267</sup> Utilizing venues and activities where adolescents routinely gather offers opportunities for youth-friendly interventions, including HIV testing. By leveraging the commonality of adolescence and group norms, comprehensive services can be offered with subsequent reduction in stigma, a sense of shared experiences, peer support, and health system efficiencies. Health care delivery, especially related to sexual and reproductive health, through school-based services, should be maximized, provided these can be youth-friendly.<sup>268</sup> Clinics should strengthen the existing system for youth and target youth who are already being screened for or diagnosed with STIs or provided reproductive health care. Service delivery should include the following components: a youth-friendly atmosphere, flexible hours, separate waiting areas for adolescents, alternative service delivery settings, and the assurance of confidentiality, including the option for self-testing.<sup>266</sup> Results from an observational study with simulated patients demonstrated that adolescent-friendly clinics improve the accessibility of HIV testing by ensuring that youth are not turned away without a test.<sup>269</sup>

**Recommendation 31: Informing an adolescent of his/her HIV-positive diagnosis is recommended as soon after diagnosis as feasible. (B II)**

Disclosure of HIV diagnosis can open the dialogue with youth about HIV and dispel myths about HIV infection, which often leads to better adherence to ART programs. Disclosure is also important for retention in care as young adolescents get to understand why they have to meet regularly with health care professionals.<sup>270–272</sup> Disclosure to adolescents should take into account their stage of development and other factors. If disclosing to minor adolescents, such disclosure should include parental notification. Support for older adolescents, whose results should be given confidentially, to facilitate their diagnosis



disclosure to parents, family members, peers, and sexual partners is also essential for coping and the ability to engage in taking medications and in prevention activities.<sup>270,273,274</sup>

**Recommendation 32: A transition plan between pediatric and adult HIV care is recommended. (B II)**

Transition programs are needed to effectively transition HIV-positive adolescents from pediatric HIV care to more independent adult HIV care. A well-managed transition can lead to improved adherence to both care and treatment.<sup>275</sup> Adolescents on ART may present with neurocognitive and mental health challenges, may be socially stigmatized, and may face difficulty in having successful sexual relationships.<sup>276</sup> These issues often evolve into major obstacles when transitioning from adolescent to adult HIV care, posing a significant obstacle to achieving and maintaining viral suppression.

**Metrics for and Monitoring of the HIV Care Continuum**

Measuring the HIV care continuum from diagnosis to viral suppression has become critical to evaluating the success of HIV responses.<sup>8,11,277</sup> However, monitoring the continuum is challenged by a lack of clarity regarding methodology and incomplete and/or fragmented data infrastructure in many settings. There have been very few estimates covering the full spectrum of stages of the continuum, produced for a complete jurisdiction, and covering an extended time frame.<sup>278-280</sup> There is a lack of consensus regarding the metrics to be included in estimating the HIV care continuum, and measurement methodologies and standards of published continua are often not well described.<sup>280-283</sup> This lack of consensus compromises the ability to interpret and compare continuum results within jurisdictions over time and across geographic settings.

In order to better align with the proposed UN 90-90-90 targets, a simplified, but comprehensive, 4-stage continuum of HIV care is proposed to capture (1) the proportion of PLHIV who have received their diagnosis (the first 90), (2) the proportion of PLHIV who are linked to care, (3) the proportion of PLHIV who are on ART, and (4) the proportion of PLHIV who are virally suppressed. The estimated number of PLHIV is the common denominator for all indicators. It is important to consider that the 90-90-90 targets use a floating denominator and that achieving 90-90-90 translates into a 90% tested-81% on ART-73% virally suppressed HIV care continuum.

As described in Table 3, the HIV care continuum should be (1) representative of the complete geographic area in question, (2) internally consistent, and (3) longitudinally monitored. Representativeness requires that the complete population of PLHIV in the geographic setting be accounted for. Internal consistency requires that the numerator from each continuum stage is also represented in its denominator. For example, all those classified as “diagnosed” are captured within the estimated prevalent population (“estimated HIV infected”), those classified as “on ART” are also classified

as diagnosed, and those classified as “suppressed” are also classified as on ART. Further, the number of people estimated to have HIV infection is the overall denominator, and numerators of the subsequent stages use this single denominator to derive proportions.

The goal is to use metrics that are practical, feasible, and as simple as possible to enable accurate monitoring of the HIV care continuum. Programs may need to develop multiple monitoring approaches beyond the focused recommendations mentioned subsequently to assure a comprehensive quality response. Nevertheless, comprehensive and transparent reporting of the measurement methodology for each step of the continuum is imperative for internal decision making and external comparison. Incomplete reporting may result in suboptimal program assessment and suboptimal resource allocation decisions. If the recommended continuum is not followed, then a clear explanation of the methodology that is used should be included to alert end users and to avoid inappropriate comparison of results with continua that use the recommended approach.

**Recommendation 33: A standardized method should be used to estimate the total number of PLHIV (diagnosed and undiagnosed) within a geographic setting. (A IV)**

For the sake of comparability, the use of a common method to establish the denominator for the HIV care continuum is critical to unbiased evaluation of the progress and impact of program implementation. There are a number of estimation methods. For example, the Spectrum tool<sup>284</sup> is available and can be applied to jurisdictions with a minimal set of data elements. National and local governments may opt to use other estimation methodologies to estimate the overall number of PLHIV. It is important to standardize, validate, and publish the methodology for review. In some settings with comprehensive HIV testing, the number of people diagnosed with HIV may serve as an accurate surrogate for the number of PLHIV. The estimations for key population denominators require different methodologies, and countries are encouraged to monitor the continuum among these vulnerable and often neglected communities. Continua should be measured annually, and all proposed metrics should be expressed as period rather than point prevalence figures.

**Recommendation 34: The estimated number of PLHIV in the geographic setting should be the overall denominator for the HIV care continuum. (A IV)**

The estimated number of PLHIV in a given geographic setting during a given calendar year is taken as the denominator. No exclusions are made pertaining to the status or risk group of the individual. It is expressed as both a count and a proportion of the total population within the geographic setting. This indicator serves as the denominator for all the remaining steps in the HIV care continuum and is crucial for the population-based framework of the continuum. Although

it is the most challenging step in the continuum to estimate, it is key for monitoring the success of HIV case-finding efforts. To prioritize and monitor efforts to increase HIV diagnosis, an estimate of the undiagnosed fraction is required. This measure is the cornerstone of the entire continuum framework and is required to assess the relative priority or success of efforts to improve case finding and access to HIV care and treatment. In some settings, the estimated number of PLHIV is nearly the same as new diagnoses—in these settings, if the epidemiologic experts agree, the new diagnoses can be used to estimate the number of PLHIV.

**Recommendation 35: Collection of a minimum set of 5 data elements should be considered to populate the HIV care continuum. (A IV)**

- **Estimated number of PLHIV**
- **Number and proportion of PLHIV who are diagnosed as having HIV**
- **Number and proportion of PLHIV who are linked to care (optional)**
- **Number and proportion of PLHIV on ART**
- **Number and proportion of PLHIV on ART who are virally suppressed**

The estimated number of PLHIV (diagnosed and undiagnosed) serves as the first data element and the overall denominator for the HIV care continuum. Not standardizing the denominator can lead to bias toward using smaller denominators to inflate reported success with implementing the continuum and also prohibits the comparison of program success both within the program and with other programs.

The numerator for the first step in the continuum should be the total number of people diagnosed with HIV. The indicator should be expressed both as a count and as the proportion of the estimated number of PLHIV within the geographic setting.

The second step in the continuum is the number and proportion of PLHIV who are linked to care. Although linkage to care is a critical step toward starting ART and ultimately achieving viral suppression, this indicator is considered optional. Linkage to care is useful to monitor to ensure that people who are diagnosed with HIV have access to ART as soon as feasible for their health and to prevent HIV transmission. In some settings, linkage to care is equivalent to starting ART, whereas in others, there may be considerable delay while waiting to access ART and achieve viral suppression. In those settings, linkage proportions may be high without achieving on ART and “viral suppression” targets. The definition of “linkage to care” has a wide variety of definitions, however, it is important to standardize its measurement within programs so that it includes everyone newly diagnosed with HIV and uses a reliable measure of whether they have accessed care. Common definitions of linkage to care include at least 1 CD4 count or other laboratory value, attendance of at least 1 clinic appointment, and/or pickup of ARV prescriptions among others.

The third step in the continuum is the total number of PLHIV on ART. It is defined as the number receiving ART

at least once within the calendar year. The indicator should be expressed as both the number of PLHIV on ART and as a proportion of the number of PLHIV within the geographic setting. This is a key element of the continuum and determines the potential for sustained viral suppression, which is the ultimate objective of the continuum. The number of PLHIV picking up medications can be determined from providers or others as a surrogate measure and does not require clinical evaluation and/or other tests.

The numerator for the fourth step in the HIV care continuum is the total number of PLHIV with documented viral suppression within a given geographic setting (viral suppression is defined as at least 1 measurement of the lowest quantifiable level [eg, HIV RNA <200, 500, or 1000 copies/mL] during the measurement period). This indicator should be expressed as both a count and a proportion of the number of PLHIV within the geographic setting. Viral suppression among PLHIV is the single most important common goal of HIV care and prevention and the key element of the continuum.

**Recommendation 36: Where possible, jurisdictions should consider longitudinal cohort measurement of HIV service utilization and treatment outcomes to identify the means to maximize viral suppression through ensuring early access to ART and retention in care. (A IV)**

In addition to the annual determination of the basic continuum measures, there is also considerable value in taking a longitudinal cohort approach to follow individuals living with HIV infection. Cohort methods allow for monitoring and evaluation of HIV service utilization and outcomes among individuals over time. Specifically, longitudinal cohort analyses from the time of diagnosis to ART initiation and viral suppression (including ART discontinuation and reentry, death, loss to follow-up, and other outcomes) can inform efforts to identify interventions at various stages of the HIV care continuum, the patient populations most in need of intervention, and those most likely to benefit.<sup>285</sup> Although the longitudinal cohort approach may appear to be complex, it has been successfully implemented in a number of diverse settings, including directly observed treatment, short-course-based TB control, noncommunicable chronic diseases, and also HIV in some settings, including in British Columbia, Canada, Malawi, Rwanda, and Switzerland.<sup>279,286–288</sup>

Attrition at different stages along the HIV care continuum is heterogeneous. It comprises individuals who drop-out of HIV treatment for the first time, experience multiple treatment discontinuations, as well as those lost to HIV care entirely (ie, discontinued regular physician follow-up and diagnostic testing). The sometimes cyclical process of engagement, disengagement, and reengagement in HIV care has been referred to as continuum “churn” and has been cited as a crucial component of HIV monitoring. Persistence with ART, or sustained engagement (as opposed to adherence that measures the number of prescribed doses of ART

**Table 3. Recommended Standards for Measurement of the HIV Care Continuum.**

	HIV Infected	HIV Diagnosed	Linked to Care (Optional)	On ART	Virologically Suppressed
<b>Definition</b>	Estimated number of PLHIV, diagnosed or undiagnosed, within the measurement period. Ideally presented with low/high uncertainty bounds.	Number and proportion of people diagnosed with HIV and presumed alive at the end of the measurement period. Should be expressed as a number and percentage of estimated PLHIV (see definition).	Number and proportion of people diagnosed with HIV who are subsequently linked to HIV care, preferably within a limited time period. Should be expressed as a number and percentage of estimated PLHIV (see definition).	The number and proportion of people diagnosed with HIV and on ART. Usually defined as those receiving at least 1 ART dispensation within the measurement period. Should be expressed as a number and percentage of estimated PLHIV (see definition).	The total number of people diagnosed with HIV on ART with documented viral suppression (see below for definition) in clinical/administrative health records, within the measurement period. Should be expressed as a number and percentage of estimated PLHIV (see definition).
<b>Numerator</b>	The estimated number of PLHIV alive at the end of a given calendar year. This estimate includes the number of diagnosed and undiagnosed PLHIV.	The total number of PLHIV with documented HIV-positive status in clinical or administrative health records. An HIV-positive diagnosis should be defined as having at least 1 confirmed positive HIV test.	The total number of PLHIV who are linked to care, preferably within a limited time period (eg, 3-6 months). The definition of linked to care could include attending at least 1 clinical care visit and/or acquiring laboratory tests and/or prescriptions that could serve as a surrogate marker for at least 1 care visit.	The total number of PLHIV on ART.	Number of persons whose last pVL during the measurement period was <200 copies/mL (or lowest quantifiable level below <1,000 copies/mL). If no pVL records are available for an individual during the measurement period, the individual should be classified as nonsuppressed.
<b>Denominator</b>	–	Estimated number of PLHIV.	Estimated number of PLHIV.	Estimated number of PLHIV.	Estimated number of PLHIV.
<b>Classification*</b>	Fixed, modeled estimate	Fixed, empirical figure	Fixed, empirical figure	Time-variable, empirical figure	Time-variable, empirical figure
<b>Measurement tools</b>	National estimates are available via the UNAIDS Spectrum tool, CDC NHBS reports, or the forthcoming CDC local estimation tool.	The best possible measure will require linked individual-level data on HIV testing, ARV dispensation, virologic testing, and vital statistics to ensure internal consistency, that is, migrants with no test result available or those tested nonnominally are captured in this and subsequent stages. Alternatively, aggregate-level data on the number of diagnosed individuals, which can distinguish between unique individuals, may be acceptable.	The most rigorous measurement would be unique identifier linkage of person newly diagnosed with HIV with evidence of one or more visits to a clinic where they receive HIV care. Where this sort of unique identifier cohort individual data is unavailable (most settings), the next best measurement is to count the number of PLHIV in care during the reporting period. Comparing the change in the number of people in care with the number of people newly diagnosed with HIV during the reporting period and overall can provide rough estimates of linkage effectiveness. Without name-based linkage systems, the people linked to care may not be the same as those newly diagnosed during the reporting period.	The best possible measure will require linked individual-level data on ARV dispensation and virologic testing data to ensure internal consistency. Alternatively, aggregate-level data on the number of those dispensed medication, which can distinguish between unique individuals, may be acceptable.	The best possible measure will require individual-level virologic testing data. Alternatively, aggregate-level sampling data on the number of those virologically suppressed, which can distinguish between unique individuals, may be acceptable.

(continued)

Table 3. (continued)

	HIV Infected	HIV Diagnosed	Linked to Care (Optional)	On ART	Virologically Suppressed
Technical notes	If data on mortality and outmigration are available for PLHIV within a given jurisdiction, it should be incorporated into the calculations.	This metric should exclude deaths prior to the end of the follow-up period and, if possible, be adjusted for estimated outmigration (persons who moved out of the jurisdiction or transferred care). It should include immigrants (persons who moved to the jurisdiction after HIV diagnosis elsewhere).	Unique identifier-based linkage provides the most accurate measure of this indicator. Additionally, a solid definition of care is useful. Although most programs use single indicators of linkage such as clinic visit or laboratory tests in some cases, these may not signify meaningful linkage in terms of getting on ART or viral suppression if patients do not return to the clinic.	We distinguish between dispensation or pickup and prescription of ARV medication. Although the latter may be used if the former is not available, it should be acknowledged that information on prescription, as opposed to dispensation, will result in higher “on ART” estimates.	The proposed threshold for viral suppression is drawn from current evidence on the individual and public health benefits of treatment. The threshold may change as more conclusive evidence becomes available.
Challenges	Inherent imprecision and uncertainty, lack of data in some regions, and a challenge to calculate for subregions.	Heavily dependent on quality of HIV surveillance system. It is crucial for areas to estimate outmigration or care transfer if possible to provide an accurate picture of indicators of retention in care and viral suppression.	The linkage to care indicator, while used in many settings, is often difficult to interpret without unique identifier-based linkage and/or cohort approach from diagnosis to care to ART to viral suppression. Great care is needed to both define meaningful linkage and to interpret the data, given the possibility of people moving in and out of care throughout the course of HIV infection.	Specifying a single ART dispensation will not eliminate those on ART only for a limited duration of the measurement period. Data requirements at the population level may be unavailable in many jurisdictions.	Specifying the latest pVL measurement will limit, but not eliminate, those suppressed only for a limited duration of the measurement period. Data requirements at the population level may be unavailable, as some regions do not perform virologic monitoring as part of standard clinical care. Laboratory or other constraints may necessitate a higher threshold of viral suppression in some jurisdictions.

Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; CDC, Centers for Disease Control and Prevention; NHBS, National HIV Behavioral Surveillance; pVL, plasma viral load; PLHIV, people living with HIV; UNAIDS, Joint United Nations Programme on HIV/AIDS.

<sup>a</sup>Metrics can be classified as either fixed (once an individual reaches this stage, he or she cannot move backward) or time variable (an individual's status can change from one period to the next). The modeled estimate necessary for quantifying the number of HIV-infected individuals should be distinguished from the empirical figures—the highest quality empirical figures are ideally true counts and proportions of individuals who are diagnosed, on ART, and virally suppressed. Although estimations for PLHIV are the norm, in some settings with very low incidence, the number of HIV diagnosed could provide the empirical data for PLHIV.



**Table 4.** Guidance on Issues Related to Optimizing the HIV Care Continuum for Select Key Populations.**Women**

- Prioritize and increase women's access to and retention in HIV services along the continuum of HIV care, including through gender-sensitive programming
- Integrate community-based support services for women within HIV care, including peer-based programs and family-based programs that engage partners and family members and, at a minimum, offer direct referral to such services for women living with HIV
- Screen for and implement interventions to address food insecurity among women living with HIV
- Screen for physical and emotional abuse and violence (or the risk of experiencing violence) among women across the HIV care continuum
- Conduct nonstigmatizing discussions of pregnancy and parenting choices and the provision of family planning services to support the full range of sexual and reproductive rights of women living with HIV
- Implement interventions to scale-up access to and retention in HIV care and treatment for pregnant and breastfeeding women living with HIV. Such interventions should also include socioeconomic support
- Scale-up pediatric HIV services for infants born to HIV-positive mothers to promote both child and maternal health
- Tailor ART-prescribing practices to consider women's use of other medications (eg, contraceptives), as well as potential side effects in women
- Address the challenges faced by younger women living with HIV across the HIV care continuum

**MSM**

- Develop and adopt standards for the provision of culturally competent care and the dissemination of information/educational materials in clinical programs for all MSM to address medical mistrust, promote confidentiality, and minimize stigma, with specific attention to MSM from racial or ethnic minority populations
- Offer supporting services in community-based settings in order to reach MSM who may not access HIV testing services in clinical settings
- Offer STI testing, including screening for syphilis, chlamydia, and gonorrhea in all relevant anatomical sites; screen for viral hepatitis and vaccinate susceptible MSM for HAV and HBV; vaccinate MSM aged less than 26 years for HPV; and provide anal examination for HPV-associated pathology
- Facilitate the linkage to care of MSM youth at HIV testing sites through direct referral to MSM peer navigators

**Transgender individuals**

- Develop and adopt standards for the provision of culturally competent care and the dissemination of information/educational materials in clinical programs for transgender individuals to address medical mistrust, promote confidentiality, and correct misperceptions regarding HIV treatment and transgender-specific medical care
- Consult with or refer HIV-positive transgender individuals on ART who wish to start hormone therapy to a clinician experienced in transgender medical care

**Sex workers**

- Tailor HIV prevention, treatment, and care interventions for sex workers, including voluntary HIV, STI, and viral hepatitis (HBV and HCV) screening; condom promotion; and access to ART
- Implement programs to scale-up access and address barriers to ART which are led by and for sex workers living with HIV

**Migrant and unstably housed populations**

- Screen individuals for their housing situation
- Ensure that the basic subsistence needs of unstably housed persons living with HIV are met (eg, access to housing, food, clothing, and hygiene)
- Use evidence-based interventions to address structural barriers to care for unstably housed individuals
- Implement population-tailored strategies to improve engagement and retention in HIV care for migrant and mobile populations

**Substance users**

- Scale-up evidence-based treatment for substance use, in particular, opioid substitution therapies
- Implement time-limited DAART with substance users at high risk of nonadherence
- Conduct comprehensive and integrated assessments for and provide treatment of comorbid psychiatric illnesses, in particular, depression, among substance users

**Incarcerated populations**

- Offer universal HIV testing, particularly in jurisdictions with hyperendemic rates of incarceration, so that the offer of HIV testing in correctional health care settings mirrors that in community health settings
- Implement interventions to prevent HIV transmission among populations that move into, dwell in, or leave correctional facilities, while delivering general interventions that decrease intimate partner/sexual violence, promote harm reduction, and address substance use
- Ensure that health services in jails and prisons follow international guidelines for HIV care, including for the management of HIV comorbidities that occur at high frequency in incarcerated populations
- Promote 2-way, comprehensive communication between correctional and community HIV providers to ensure that there are no gaps in care, treatment, and support services as people transition to and from their communities and correctional facilities

Abbreviations: ART, antiretroviral therapy; DAART, directly administered antiretroviral therapy; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HPV, human papilloma virus; MSM, men who have sex with men; STI, sexually transmitted infection.

**Table 5.** Recommendations for Future Research on Optimizing the HIV Care Continuum.**Optimizing the HIV care environment**

- Impact of actions taken to reduce stigma and discrimination and address mental health from a quality-of-life perspective (eg, interventions and programs) on these issues as well as on HIV-related health outcomes
- Use of standardized, validated measures of multiple stigma and mental health dimensions to ensure comparability across settings and over time
- Measurement and identification of ways in which to reduce stigma at the structural level (eg, in the community, broader human rights, and policy context)
- Impact of criminalizing the conduct of key populations on health service utilization and HIV-related health outcomes

**Increasing HIV testing coverage**

- Impact of eliminating pretest counseling
- Comparative analysis of using 1-minute rapid test results
- Self-testing and its impact on linkage to care
- Impact of the use of mass media on getting tested
- Cost–benefit analysis of doing mass testing in medium/small cities versus targeted testing
- Cost–benefit analysis of a national (provincial) testing day versus all year-round targeted testing versus promoting HIV testing at traditional medical venues
- Cost–benefit analysis of eliminating Western blot as a confirmatory test and using CD4 count and/or viral load testing instead
- Impact of couple-focused testing, counseling, and care on participant retention, adherence to treatment and care, and uptake of ancillary services such as family planning and condom use
- Cost analysis of focused testing for couples
- Operational factors that maximize uptake and completion of HIV testing in clinical HIV screening programs, including the optimal framing and logistics of the actual HIV test offer, and the type of worker who should either offer or provide the test to maximize patient willingness to test
- Factors that can help close the gap between the volume of patients in large clinical settings who are willing to test and those who successfully receive a test
- Best mix of community mobilization strategies and service delivery approaches for maximal coverage and yield of HIV testing in appropriate low-, middle-, and high-income settings
- Cost-effectiveness and yield of different combinations of community approaches to assist public health implementers with limited resources
- How to optimize the benefits of HIV self-testing from the perspective of appropriate venues/settings, enhancing awareness, improving uptake, and ensuring linkage to care for those who use this modality
- Whether and how to integrate partner or couples testing into routine clinical care and, if so, for which populations; the impact of couples testing on linkage to care (for both partners); and differences in the impact of couples testing on different at-risk groups
- Appropriate settings/venues for deployment of point-of-care antigen/antibody tests, incorporation of these tests into public health partner services programs, and potential impact of these tests on molecular epidemiologic analysis and outreach related to clusters of individuals newly infected with HIV

**Increasing linkage to HIV care**

- Standardization of the measurement of meaningful linkage to care
- Barriers and facilitators to linkage to care for special and general populations
- Interventions or combination of interventions to overcome barriers to linkage to care
- Potential role of financial incentives for improving linkage to care
- Linkage to care facilitated by community health workers and patient navigators
- Provision of home-based services to reduce transportation barriers for HIV-positive patients
- Task shifting of care to nonphysician-based systems
- Integration of care within other health care services to allow for better accessibility and reduced stigma
- Decentralization of care within the context of HIV treatment scale-up

**Increasing HIV treatment coverage**

- Optimal frequency of clinical and laboratory monitoring of individuals on ART
- Impact of future HIV treatment modalities, including long-acting ARVs

**Increasing retention in HIV care**

- Incorporation of a validated core set of metrics, ideally in electronic health record systems for retention monitoring
- Interventions for successful retention in care in high-income versus low- and middle-income country settings, given the very different resource base and socioeconomic support networks available
- Whether technology tools such as cell phones can support long-term retention in care
- Whether interventions such as enhanced face-to-face contact and appointment reminders can make a difference in return-to-clinic rates
- Potential role of financial incentives to support treatment retention and of financial assistance or vouchers to address care costs and food, monetary, and travel constraints
- Dissemination and sharing of best practices to retain PLHIV in care
- Alternative models of care delivery, including pharmacy-only visits, visits with nonphysician providers only, and “community adherence” models in which small groups of clients rotate pill refill duties
- Utility and cost-effectiveness of home-based HIV care

(continued)

**Table 5.** (continued)**Increasing ART adherence and viral suppression**

- Magnitude or level of ART adherence needed to maintain virologic suppression
- Optimal duration and timing of the window of opportunity to launch adherence interventions, the pattern of nonadherence, and drug resistance by class of ARV drugs
- Effectiveness of financial incentives or economic empowerment to achieve and sustain virologic suppression
- Impact of ART desimplification from the current QD single-tablet regimens to QD multitablet regimens on virologic outcomes
- Effectiveness of combining different types of interventions (eg, technology—mHealth versus psychological versus structural versus social) using factorial designs to allow optimization of the effects/impacts on virologic suppression
- Cost-effectiveness of evidence-based ART adherence interventions effective in achieving sustained virologic suppression to determine how differing levels of ART adherence may impact costs for ART utilization

**Metrics and monitoring**

- Cloud-based cohort monitoring and evaluation of the continuum of care
- Real-time monitoring and evaluation to guide program implementation
- Impact of continuum and cohort monitoring on implementation efficiency and cost savings
- Impact of the use of the continuum methodology on viral suppression
- Health and economic impact of implementing a continuum measurement system nationally and standardizing its use across geographic subregions

**Women**

- Approaches to addressing the challenges faced by younger women living with HIV across the HIV care continuum
- Safest and most effective options for ART in pregnant women (prospective studies across different contexts)
- Clinical implications of interactions between ART and other medications or comorbidities among women living with HIV, as well as the effects of menopause on response to ART
- Effective and appropriate strategies for couple-based approaches to HIV treatment and care, including the provision of appropriate sexual and reproductive health services to discordant couples

**Adolescents**

- Youth support or types of family support interventions that are beneficial to youth engagement in care
- Unanticipated adverse outcomes from engaging youth without family support
- Social and legal barriers facing key populations of youth (eg, LGBT, substance using, and sex workers) and how programs can improve outcomes in the context of these social constraints
- Lessons that can be learned from the engagement of adolescents/young adult women in PMTCT programs whether they do as well as adult women and what program enhancements have been used
- Successful program approaches to support adherence among youth (both perinatally and behaviorally infected) for HIV treatment and prevention
- Key youth-serving institutions and programs as well as social media and mobile technology that need to be engaged to best reach youth with prevention, testing, and care messages and approaches
- Disaggregation of data by age and gender for youth: 10 to 14 years, 15 to 19 years, and 20 to 24 years
- Research on the best forms of contraception for adolescent women

**MSM**

- Development of culturally tailored interventions to increase the rates of HIV testing, linkage, and engagement in care and rates of virologic suppression among HIV-infected young MSM in different geographic regions of the world
- How each of the steps of the HIV care continuum can be optimized for racial and ethnic minority MSM in different geographic regions of the world
- Whether interventions that address structural homophobia in different parts of the world result in improving the involvement of MSM in each part of the continuum
- Culturally tailored interventions for transgender women and men who are at increased risk for HIV or are living with HIV, so that they are not lumped into interventions for cisgender MSM

**Transgender individuals**

- Ways to involve and engage transgender individuals in HIV risk reduction practices
- Ways by which to provide health services to transgender individuals so that they are not stigmatized
- Modalities by which at-risk transgender individuals can receive information, diagnosis, and treatment for STIs and/or HIV
- Management of risks associated with concomitant cross-gender hormone therapy and ART

**Sex workers**

- Research to pilot and scale-up novel multilevel and structural interventions to improve linkages to the HIV care continuum for sex workers
- Ways to mitigate structural-level barriers (eg, criminalization of sex work, HIV, and violence) that result in suboptimal HIV treatment and care outcomes for sex workers, including female, male, and trans sex workers
- Consideration of integrated HIV treatment and care services within broader primary care and sexual and reproductive health services, which are safe, confidential, and tailored to the unique needs of female, male, and trans sex workers living with HIV

(continued)

**Table 5.** (continued)

---

- Evaluation of community empowerment and sex worker-led HIV interventions to address stigma and discrimination and optimize engagement and retention in HIV treatment and care for sex workers
- Implementation science on ARV distribution and retention (eg, mobile ART distribution, text messages)
- Increased community-based research in partnership with sex workers on feasibility and community engagement in biomedical interventions (eg, TasP, PEP, and PrEP)

**Migrant and unstably housed populations**

- Interventions to enhance access to the HIV care continuum for migrant and mobile groups, including novel strategies to improve entry, linkage, and retention in ART for those recently diagnosed with HIV
- Extent to which migration and mobility patterns may explain “leakages” in the HIV care continuum
- Novel strategies to facilitate cross-border access to HIV care for migrant populations (eg, cross-border insurance schemes)

**Substance users**

- Interventions for ART-naïve patients with substance use disorders
- Creation of transitional models that sustain the long-term benefit of effective interventions
- Evaluation of the effectiveness, feasibility, and cost-effectiveness of comanaging HIV and opioid substitution therapy
- Efficacy of educational counseling, adherence case management, timer and reminder interventions, and peer-driven and family support interventions that have shown promising results in pilot studies
- Long-term home visit nursing interventions with peer support
- Novel treatments for stimulant dependence, including substitution therapies, and whether they can be paired with ART
- Implementation science to identify approaches to optimizing the combining of ART provision, addiction treatment, and harm reduction programs
- Methods for improving access and adherence to ART among those with active addiction

**Incarcerated populations**

- Effect of incarceration on continuity of/linkage to HIV care in jail settings to minimize the health consequences of interaction with the criminal justice system (including rape) and not increase the complications of HIV for any individual, including those who are transgender or inject drugs
- Ability to use the incarceration period to identify high-risk individuals who are undiagnosed and to reengage inmates in HIV care if they fell out of care prior to incarceration
- Effect of incarceration on continuity of HIV care—linkage to care after release from correctional facilities, continuity of medications during transition, and prompt linkage to community health care systems
- Factors that will minimize both the frequency and the duration of incarceration, such as decriminalization of HIV and access to bail if incarcerated

---

Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; LGBT, lesbian, gay, bisexual, and transgender; MSM, men who have sex with men; PEP, postexposure prophylaxis; PLHIV, people living with HIV; PMTCT, prevention of mother-to-child transmission; PrEP, preexposure prophylaxis; QD, once-daily; STI, sexually transmitted infection; TasP, treatment as prevention.

that were ingested), is of particular interest, as the ultimate goal of sustained viral suppression cannot be achieved without such an engagement.

### Key Populations

A number of distinct populations continue to be disproportionately affected by the HIV pandemic, including, but not limited to, women, adolescents, MSM, transgender individuals, sex workers, substance users, migrants and unstably housed people, and incarcerated populations.<sup>289–295</sup> A growing body of evidence indicates that these populations also contend with an array of challenges associated with engagement or retention in the HIV care continuum. It bears noting that racial and ethnic disparities can both exacerbate the challenges faced by key populations and result in poorer overall health outcomes.<sup>296–298</sup>

Challenges vary across key populations, but there are some common challenges among these populations, including pervasive stigma and discrimination,<sup>299,300</sup> violence,<sup>301,302</sup> mistrust of medical providers or systems,<sup>303</sup> unmet basic needs of daily living (eg, food and shelter),<sup>291,304</sup> lack of access to culturally appropriate services,<sup>305</sup> underaddressed comorbidities,<sup>306,307</sup>

and suboptimal access to evidence-based interventions due to these not being offered or brought to an appropriate level of scale.<sup>289,308</sup> Population-specific programs and policies that address these challenges are urgently needed. Further, although a growing body of evidence indicates that peer-delivered programs often help extend the reach, coverage, acceptability, and effectiveness of a range of programs,<sup>309–311</sup> these approaches remain underutilized.

A number of key populations are also subjected to human rights abuses, as well as policies and laws that criminalize them and their behavior, and thereby undermine engagement in the HIV care continuum. Further, migrant, displaced, and mobile populations often face laws that prohibit their access to universal HIV treatment and care, and some are threatened with deportation upon HIV diagnosis.<sup>312</sup> Therefore, there is an urgent need for structural reform of a range of laws and policies in order to promote full engagement in the continuum.<sup>290,313</sup> Policy reforms that seek to ensure adequate access to evidence-based programs are also needed, including those that may be deemed controversial in some settings, such as harm reduction, opioid substitution therapy, and needle–syringe and condom distribution programs.<sup>289,314</sup>



Although the development of evidence-based recommendations specific to key populations is beyond the scope of these guidelines, guidance on a series of issues specific to women, adolescents, MSM, transgender individuals, sex workers, substance users, migrant and unstably housed populations, and incarcerated populations is provided in Table 4.

### About the Authors

**Chairs:** Linda-Gail Bekker, MBChB, FCP, PhD; Julio Montaner, MD; Celso Ramos, MD, MSc; Renslow Sherer, MD. **Section chairs:** Francesca Celletti, MD; Blayne Cutler, MD, PhD; François Dabis, MD, PhD; Reuben Granich, MD, MPH; Alan Greenberg, MD; Shira Goldenberg, PhD; Mark Hull, MD; Thomas Kerr, PhD; Ann Kurth, PhD, RN, MPH; Kenneth Mayer, MD; Lisa Metsch, PhD; Nelly R. Mugo, MBChB, MMed, MPH; Paula Munderi, MD; Jean Nachega, MD, PhD; Bohdan Nosyk, PhD; Jorge Saavedra, MD; Theresa Wolters, MA; Benjamin Young, MD, PhD; José M. Zuniga, PhD, MPH. **Panelists:** Bruce Agins, MD, MPH; K. Rivet Amico, PhD; Josip Begovac, MD, PhD; Chris Beyrer, MD, MPH; Pedro Cahn, MD, PhD; Gus Cairns, MA; Mardge Cohen, MD; Kathleen Deering, PhD; Carlos del Rio, MD, MPH; Ricardo S. Diaz, MD, PhD; Julia C. Dombrowski, MD, MPH; Rupali Doshi, MD, MS; Wafaa El-Sadr, MD, MPH, MPA; Donna Futterman, MD; Anna Maria Geretti, MD, PhD, MRCPath; Giovanni Guaraldi, MD; Jim Halloran, RN, MSN, CNS; Christopher M. Gordon, PhD; Shoshana Kahana, PhD; Javier Lama, MD, MPH; Viviane Dias Lima, MSc, PhD; Nathan Linsk, PhD; Antonella D'Arminio Monforte, MD, PhD; Mark Nelson, MD; Eyerusalem Negussie, MD, MPH (is a staff member of the World Health Organization. The author alone is responsible for the views expressed in this article and they do not necessarily represent the decisions, policies, or views of the World Health Organization); Praphan Phanuphak, MD, PhD; James Scott, PharmD, MMed; Douglas Shaffer, MD, MHS; Kate Shannon, PhD, MPH; Anne Spaulding, MD, MPH; Carlos Valerio, JD, MPH; Zunyou Wu, MD, MPH, PhD; Anna Zakowicz, MA, MIH; Carmen Zorrilla, MD.

### Acknowledgments

The Chairs thank IAPAC for serving as the international advisory panel's secretariat and the following individuals who were instrumental to the development of these guidelines: José M. Zuniga, PhD, MPH, Imane Sidibé, MSc, and Sindhu Ravishankar, MPhil (IAPAC; guidelines conception, and technical support, respectively); Cynthia Lyles, PhD, and Linda Koenig, PhD, (Centers for Disease Control and Prevention; providing access to and assisting with review of CDC Prevention Synthesis Project database for systematic review); Kathryn E. Buggraf, MPH; Anne E. Byers, MPH; Raissa Dickinson MPH; D. Dennis Flores, MSN, ACRN; Natalie M. Leblanc, BSN, MPH; Petra Lolic, MPH; Jacquelyn Malasky, MPH; Avani Patel, MPH; Kenisha M. Peters, MPH; Cathy Puskas, MSc; Cho Hee Shrader, MPH; Sara Wuite, MPH; Qian Zhang, MPH (systematic review); and Bandana Malhotra, MBBS, DVD (medical editing).

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Development of the guidelines was jointly sponsored by IAPAC and the US National Institutes of Health (NIH), Office of AIDS Research (OAR).

### Supplemental Material

The Supplemental Appendix 1 – Methodology is available at <http://jia.sagepub.com/supplemental>.

### References

- Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. *PLoS One*. 2013; 8(12):e81355.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011; 365(6):493–505.
- Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. *BMJ*. 2009;338:b1649.
- De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. *JAMA*. 2000; 283(9):1175–1182.
- Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. *Lancet*. 2006;368(9534):531–536.
- Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet*. 2009;373(9657):48–57.
- Montaner JS, Lima VD, Harrigan PR, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. *PLoS One*. 2014; 9(2):e87872.
- Joint United Nations Programme on HIV/AIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2014. Web site. <http://www.unaids.org/en/resources/documents/2014/90-90-90>. Accessed October 15, 2015.
- Joint United Nations Programme on HIV/AIDS. 15 by 15: a global target achieved. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2015. Web site. [http://www.unaids.org/sites/default/files/media\\_asset/UNAIDS\\_15by15\\_en.pdf](http://www.unaids.org/sites/default/files/media_asset/UNAIDS_15by15_en.pdf). Accessed October 15, 2015.
- Joint United Nations Programme on HIV/AIDS. World AIDS Day 2014 Report—Fact sheet. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2014. Web site. <http://www.unaids.org/en/resources/campaigns/World-AIDS-Day-Report-2014/factsheet>. Accessed October 15, 2015.
- Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to

- test-and-treat strategies for prevention of HIV infection. *Clin Infect Dis*. 2011;52(6):793–800.
12. Granich R, Gupta S, Montaner J, Williams B, Zuniga JM. Pattern, determinants and impact of HIV spending on care and treatment in 39 high burden countries. *J Int Assoc Provid AIDS Care*. 2015. Pending publication.
  13. Pineirua A, Sierra-Madero J, Cahn P, Guevara Palmero R, Martinez E, Young B. The HIV care cascade in Latin America: challenges and opportunities. *Lancet*. 2015;15(7):833–839.
  14. Centers for Disease Control and Prevention. Understanding the HIV Care Continuum. Centers for Disease Control and Prevention; 2014. Web site. [http://www.cdc.gov/hiv/pdf/dhap\\_continuum.pdf](http://www.cdc.gov/hiv/pdf/dhap_continuum.pdf). Accessed October 15, 2015.
  15. Govindasamy D, Meghij J, Negussi EK, Baggaley RC, Ford N, Kranzer K. Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings—a systematic review. *J Int AIDS Soc*. 2014;17(1):19032.
  16. Beyrer C, Sullivan P, Sanchez J, et al. The increase in global HIV epidemics in MSM. *AIDS*. 2013;27(17):2665–2678.
  17. Shannon K, Strathdee SA, Goldenberg SM, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. *Lancet*. 2015;385(9962):55–71.
  18. Baral SD, Friedman MR, Geibel S, et al. Male sex workers: practices, contexts, and vulnerabilities for HIV acquisition and transmission. *Lancet*. 2015;385(9964):260–273.
  19. Poteat T, Wirtz AL, Radix A, et al. HIV risk and preventive interventions in transgender women sex workers. *Lancet*. 2015;385(9964):274–286.
  20. Arreola S, Santos GM, Beck J, et al. Sexual stigma, criminalization, investment, and access to HIV services among men who have sex with men worldwide. *AIDS Behav*. 2015;19(2):227–234.
  21. Lehman JS, Carr MH, Nichol AJ, et al. Prevalence and public health implications of state laws that criminalize potential HIV exposure in the United States. *AIDS Behav*. 2014;18(6):997–1006.
  22. Canadian HIV/AIDS Legal Network. A Human Rights Analysis of the N'djamena model legislation on AIDS and HIV specific legislation in Benin, Guinea, Guinea Bissau, Mali, Niger, Sierra Leone and Togo. Toronto: Canadian HIV/AIDS Legal Network; 2007. Web site. [http://www.aidslaw.ca/site/wpcontent/uploads/2013/03/LN\\_HumanRtLegislnRvw\\_en.pdf](http://www.aidslaw.ca/site/wpcontent/uploads/2013/03/LN_HumanRtLegislnRvw_en.pdf). Accessed October 15, 2015.
  23. World Health Organization. *Report of the WHO European Region Technical Consultation, in collaboration with the European AIDS Treatment Group (EATG) and AIDS Action Europe (AAE), on the Criminalization of HIV and Other Sexually Transmitted Infections*. Copenhagen: World Health Organization; 2006. Web site. <http://www.hivlawandpolicy.org/sites/www.hivlawandpolicy.org/files/WHO%20consultation%20on%20crim%20laws.pdf>. Accessed October 15, 2015.
  24. Lazzarini Z, Bray S, Burris S. Evaluating the impact of criminal laws on HIV risk behavior. *J Law Med Ethics*. 2002;30(2):239–253.
  25. Burris S, Beletsky L, Bureson J, Case P, Lazzarini Z. Do criminal laws effect HIV risk behavior? An empirical trial. *Ariz St L J*. 2007;39:467–517.
  26. Galletly CL, Glasman LR, Pinkerton SD, Difrancesco W. New Jersey's HIV exposure law and the HIV-related attitudes, beliefs, and sexual and seropositive status disclosure behaviors of persons living with HIV. *Am J Public Health*. 2012;102(11):2135–2140.
  27. Galletly CL, Pinkerton SD. Preventing HIV transmission via HIV exposure laws: applying logic and mathematical modeling to compare statutory approaches to penalizing undisclosed exposure to HIV. *J Law Med Ethics*. 2008;36(3):577–584.
  28. Horvath KJ, Weinmeyer R, Rosser S. Should it be illegal for HIV-positive persons to have unprotected sex without disclosure? An examination of attitudes among US men who have sex with men and the impact of state law. *AIDS Care*. 2010;22(10):1221–1228.
  29. National Institute of Allergy and Infectious Diseases. *Scientific Evidence on Condom Effectiveness for Sexually Transmitted Disease (STD) Prevention*. Bethesda, DC: National Institute of Allergy and Infectious Diseases; 2001. Web site. <http://www.niaid.nih.gov/about/organization/dmid/documents/condomreport.pdf>. Accessed October 15, 2015.
  30. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. *Bull World Health Organ*. 2004;82(6):454–461.
  31. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493–505.
  32. McCormack S, Dunn D. Pragmatic Open-Label Randomised Trial of Preexposure Prophylaxis: The PROUD Study. Presented at: Conference on Retroviruses and Opportunistic Infections; February 23–26, 2015; Seattle, WA.
  33. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. *AIDS*. 2006;20(1):85–92.
  34. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. *J Acquir Immune Defic Syndr*. 2005;39(4):446–453.
  35. Grubb IR, Beckham SW, Kazatchkine M, et al. Maximizing the benefits of antiretroviral therapy for key affected populations. *J Int AIDS Soc*. 2014;17(1):19320.
  36. Jurgens R, Cohen J, Cameron E, et al. Ten reasons to oppose the criminalization of HIV exposure or transmission. *Reprod Health Matters*. 2009;17(34):163–172.
  37. Cameron E. Criminalization of HIV transmission: poor public health policy. *HIV AIDS Policy Law Rev*. 2009;14(2):63–75.
  38. Lazarus JV, Curth N, Wait M, Matic S. HIV-related restrictions on entry, residence and stay in the WHO European Region: a survey. *J Int AIDS Soc*. 2010;13:2.
  39. Amon JJ, Todrys KW. Fear of Foreigners: HIV-related restrictions on entry, stay, and residence. *J Int AIDS Soc*. 2008;11:8.
  40. Mills EJ, Ford N, Singh S, Eyawo O. Providing antiretroviral care in conflict settings. *Curr HIV/AIDS Rep*. 2009;6(4):201–209.
  41. Zelaya CE, Sivaram S, Johnson SC, Srikrishnan AK, Suniti S, Celentano DD. Measurement of self, experienced, and perceived HIV/AIDS stigma using parallel scales in Chennai, India. *AIDS Care*. 2012;24(7):846–855.

42. Makoae LN, Portillo CJ, Uys LR, et al. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. *AIDS Care*. 2009; 21(11):1357–1362.
43. Trost G, Vierneisel C, Gornski H, Petrov I. The PLHIV Stigma Index in Germany: Results of the Community Initiative on HIV-Related Stigmatization. Presented at: XIX International AIDS Conference; July 22–27, 2012; Washington, DC.
44. Lorente N, Preau M, Vernay-Vaisse C, et al. Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (The ANRS-DRAG Study). *PLoS One*. 2013;8(4):e61225.
45. Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? *J Int AIDS Soc*. 2013;16(3 suppl 2):18734.
46. World Health Organization. HIV testing, treatment and prevention: generic tools for operational research. Geneva, Switzerland: World Health Organization; 2009. Web site. [http://www.who.int/hiv/pub/operational/or\\_generic\\_tools.pdf](http://www.who.int/hiv/pub/operational/or_generic_tools.pdf). Accessed October 15, 2015.
47. Pulerwitz J, Michaelis A, Weiss E, Brown L, Mahendra V. Reducing HIV-related stigma: lessons learned from Horizons research and programs. *Public Health Rep*. 2010;125(2):272–281.
48. Human Sciences Research Council. The People Living With HIV Stigma Index: South Africa 2014. South Africa: Human Sciences Research Council; 2015. Web site. <http://www.stigmaindex.org/sites/default/files/reports/Summary-Booklet-on-Stigma-Index-Survey%20South%20Africa.pdf>. Accessed October 15, 2015.
49. Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. *Ann Behav Med*. 2014; 47(3):259–269.
50. Pyne JM, Fortney JC, Curran GM, et al. Effectiveness of collaborative care for depression in human immunodeficiency virus clinics. *Arch Intern Med*. 2011;171(1):23–31.
51. Safren SA, O’Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. *Health Psychol*. 2009; 28(1):1–10.
52. Brandt R. The mental health of people living with HIV/AIDS in Africa: a systematic review. *Afr J AIDS Res*. 2009;8(2):123–133.
53. Rabkin JG. HIV and depression: 2008 review and update. *Curr HIV/AIDS Rep*. 2008;5(4):163–171.
54. Bouhnik AD, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. *Antivir Ther*. 2005;10(1):53–61.
55. Carrieri MP, Chesney MA, Spire B, et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. *Int J Behav Med*. 2003;10(1):1–14.
56. Swendeman D, Rotheram-Borus MJ. Innovation in sexually transmitted disease and HIV prevention: internet and mobile phone delivery vehicles for global diffusion. *Curr Opin Psychiatry*. 2010;23(2):139–144.
57. Druss BG, Zhao L, von Esenwein SA, et al. The Health and Recovery Peer (HARP) Program: a peer-led intervention to improve medical self-management for persons with serious mental illness. *Schizophr Res*. 2010;118(1-3):264–270.
58. Millard T, Elliott J, Girdler S. Self-management education programs for people living with HIV/AIDS: a systematic review. *AIDS Patient Care STDS*. 2013;27(2):103–113.
59. Johnson MO, Neilands TB, Dilworth SE, Morin SF, Remien RH, Chesney MA. The role of self-efficacy in HIV treatment adherence: validation of the HIV Treatment Adherence Self-Efficacy Scale (HIV-ASES). *J Behav Med*. 2007;30(5):359–370.
60. Johnson MO, Dilworth SE, Taylor JM, Neilands TB. Improving coping skills for self-management of treatment side effects can reduce antiretroviral medication nonadherence among people living with HIV. *Ann Behav Med*. 2011;41(1):83–91.
61. Wolf MS, Davis TC, Osborn CY, Skripkauskas S, Bennett CL, Makoul G. Literacy, self-efficacy, and HIV medication adherence. *Patient Educ Couns*. 2007;65(2):253–260.
62. Battersby M, Von Korff M, Schaefer J, et al. Twelve evidence-based principles for implementing self-management support in primary care. *Jt Comm J Qual Patient Saf*. 2010;36(12): 561–570.
63. Ramanathan N, Swendeman D, Comulada WS, Estrin D, Rotheram-Borus MJ. Identifying preferences for mobile health applications for self-monitoring and self-management: focus group findings from HIV-positive persons and young mothers. *Int J Med Inform*. 2013;82(4):e38–e46.
64. Tufts KA, Johnson KF, Shepherd JG, et al. Novel interventions for HIV self-management in African American women: a systematic review of mHealth interventions. *J Assoc Nurses AIDS Care*. 2015;26(2):139–150.
65. Millard T, Elliott J, Slavin S, McDonald K, Rowell S, Girdler S. The positive outlook study- a randomised controlled trial evaluating the effectiveness of an online self-management program targeting psychosocial issues for men living with HIV: a study protocol. *BMC Public Health*. 2014;14:106.
66. Millard T, McDonald K, Elliott J, Slavin S, Rowell S, Girdler S. Informing the development of an online self-management program for men living with HIV: a needs assessment. *BMC Public Health*. 2014;14:1209.
67. World Health Organization. Task shifting: global recommendations and guidelines. Geneva, Switzerland: World Health Organization; 2008. Web site. [http://www.who.int/workforcealliance/knowledge/resources/taskshifting\\_guidelines/en/](http://www.who.int/workforcealliance/knowledge/resources/taskshifting_guidelines/en/). Accessed October 15, 2015.
68. Chiambe G, Kulzer J, Nyabiage L, Bukuzi E, Penner J, Cohen C. Maximizing Human Resources by Involving Lay Health Workers in HIV Service Delivery in Kenya. Presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22, 2009. Cape Town, South Africa.
69. Ledikwe JH, Kejelepula M, Maupo K, et al. Evaluation of a well-established task-shifting initiative: the lay counselor cadre in Botswana. *PLoS One*. 2013;8(4):e61601.
70. Morris MB, Chapula BT, Chi BH, et al. Use of task-shifting to rapidly scale-up HIV treatment services: experiences from Lusaka, Zambia. *BMC Health Serv Res*. 2009;9:5.
71. Grimwood A, Fatti G, Mothibi E, Malahlela M, Shea J, Eley B. Community adherence support improves programme retention



- in children on antiretroviral treatment: a multicentre cohort study in South Africa. *J Int AIDS Soc.* 2012;15(2):17381.
72. Kenya S, Chida N, Symes S, Shor-Posner G. Can community health workers improve adherence to highly active antiretroviral therapy in the USA? A review of the literature. *HIV Med.* 2011; 12(9):525–534.
  73. Tobin KE, Tang AM, Gilbert SH, Latkin CA. Correlates of HIV antibody testing among a sample of injection drug users: the role of social and contextual factors. *AIDS Behav.* 2004; 8(3):303–310.
  74. Wilton L, Herbst JH, Coury-Doniger P, et al. Efficacy of an HIV/STI prevention intervention for black men who have sex with men: findings from the Many Men, Many Voices (3MV) project. *AIDS Behav.* 2009;13(3):532–544.
  75. Meulbroek M, Ditzel E, Saz J, et al. BCN Checkpoint, a community-based centre for men who have sex with men in Barcelona, Catalonia, Spain, shows high efficiency in HIV detection and linkage to care. *HIV Med.* 2013;14(suppl 3):25–28.
  76. Chamie G, Kwarisiima D, Clark TD, et al. Uptake of community-based HIV testing during a multi-disease health campaign in rural Uganda. *PLoS One.* 2014;9(1):e84317.
  77. Champenois K, Le Gall JM, Jacquemin C, et al. ANRS-COM\* T-EST: description of a community-based HIV testing intervention in non-medical settings for men who have sex with men. *BMJ Open.* 2012;2(2):e000693.
  78. Muhamadi L, Tumwesigye NM, Kadobera D, et al. A single-blind randomized controlled trial to evaluate the effect of extended counseling on uptake of pre-antiretroviral care in Eastern Uganda. *Trials.* 2011;12:184.
  79. Chang LW, Kagaayi J, Nakigozi G, et al. Effect of peer health workers on AIDS care in Rakai, Uganda: a cluster-randomized trial. *PLoS One.* 2010;5(6):e10923.
  80. Kabore I, Bloem J, Etheredge G, et al. The effect of community-based support services on clinical efficacy and health-related quality of life in HIV/AIDS patients in resource-limited settings in sub-Saharan Africa. *AIDS Patient Care STDs.* 2010;24(9): 581–594.
  81. Kenya S, Chida N, Symes S, Shor-Posner G. Can community health workers improve adherence to highly active antiretroviral therapy in the USA? A review of the literature. *HIV Med.* 2011; 12(9):525–534.
  82. Wang H, Zhou J, Huang L, Li X, Fennie KP, Williams AB. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. *J Clin Nurs.* 2010; 19(3-4):380–388.
  83. Ko NY, Lai YY, Liu HY, et al. Impact of the nurse-led case management program with retention in care on mortality among people with HIV-1 infection: a prospective cohort study. *Int J Nurs Stud.* 2012;49(6):656–663.
  84. Grimsrud A, Kaplan R, Bekker LG, Myer L. Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. *Trop Med Int Health.* 2014;19(9):1029–1039.
  85. Decroo T, Mondlane V, Dos Santos N, et al. Community ART Groups Support ART Access and Retention among HIV-Positive Dependent Children in rural Tete, Mozambique. Presented at: 19th International AIDS Conference; July 22-27, 2012; Washington, DC.
  86. Naar-King S, Outlaw A, Green-Jones M, Wright K, Parsons JT. Motivational interviewing by peer outreach workers: a pilot randomized clinical trial to retain adolescents and young adults in HIV care. *AIDS Care.* 2009;21(7):868–873.
  87. Wouters E, Van Damme W, van Rensburg D, Masquillier C, Meulemans H. Impact of community-based support services on antiretroviral treatment programme delivery and outcomes in resource-limited countries: a synthetic review. *BMC Health Serv Res.* 2012;12:194.
  88. Wamboga Magawa J, Mpiima D. Community ART Delivery Model for High Retention of Patients on Antiretroviral Therapy: The AIDS Support Organisation (TASO) Operational Research Findings East and Central Uganda, Resource-Limited Setting. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30-July 3, 2013; Kuala Lumpur, Malaysia.
  89. Munoz M, Bayona J, Sanchez E, et al. Matching social support to individual needs: a community-based intervention to improve HIV treatment adherence in a resource-poor setting. *AIDS Behav.* 2011;15(7):1454–1464.
  90. Wouters E, Van Loon F, Van Rensburg D, Meulemans H. State of the ART: clinical efficacy and improved quality of life in the public antiretroviral therapy program, Free State province, South Africa. *AIDS Care.* 2009;21(11):1401–1411.
  91. Chang L, Nakigozi G, Mulamba J, et al. The PeerCARE Study, a Randomized, Controlled Trial of the Impact of Peers on Linkage to Care, Preventive Care and Sexual Behaviours among PLHIV not on Antiretroviral Therapy: Baseline Findings. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Jun 30-Jul 3, 2013. Kuala Lumpur, Malaysia.
  92. Gusdal AK, Obua C, Andualem T, Wahlstrom R, Chalker J, Fochsen G. Peer counselors' role in supporting patients' adherence to ART in Ethiopia and Uganda. *AIDS Care.* 2011;23(6): 657–662.
  93. Arem H, Nakyanjo N, Kagaayi J, et al. Peer health workers and AIDS care in Rakai, Uganda: a mixed methods operations research evaluation of a cluster-randomized trial. *AIDS Patient Care STDs.* 2011;25(12):719–724.
  94. Tenthani L, Cataldo F, Chan AK, Bedell R, Martiniuk AL, van Lettow M. Involving expert patients in antiretroviral treatment provision in a tertiary referral hospital HIV clinic in Malawi. *BMC Health Serv Res.* 2012;12:140.
  95. Danel C, Gabillard D, Le Carrou J, et al. Early ART and IPT in HIV-Infected African Adults With High CD4 Count (TEMPRANO Trial). Presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
  96. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med.* 2015;373(9):795–807.
  97. Branson B, Handsfield H, Lampe M, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. Atlanta, GA: CDC; 2006. Web site. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm>. Accessed October 15, 2015.



98. Craw J, Gardner L, Rossman A, et al. Structural factors and best practices in implementing a linkage to HIV care program using the ARTAS model. *BMC Health Serv Res*. 2010;10:246.
99. Elul B, Lahuerta M, Abacassamo F, et al. A combination strategy for enhancing linkage to and retention in HIV care among adults newly diagnosed with HIV in Mozambique: study protocol for a site-randomized implementation science study. *BMC Infect Dis*. 2014;14:549.
100. Bauman LJ, Braunstein S, Calderon Y, et al. Barriers and facilitators of linkage to HIV primary care in New York City. *J Acquir Immune Defic Syndr*. 2013;64(suppl 1):S20–S26.
101. Koester KA, Morewitz M, Pearson C, et al. Patient navigation facilitates medical and social services engagement among HIV-infected individuals leaving jail and returning to the community. *AIDS Patient Care and STDs*. 2014;28(2):82–90.
102. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. *PLoS Med*. 2011;8(7):e1001056.
103. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. *AIDS*. 2012;26(16):2059–2067.
104. World Health Organization. Consolidated Guidelines on HIV Testing Services. 5Cs: Consent, Confidentiality, Counselling, Correct Results and Connection. Geneva, Switzerland: World Health Organization; 2015 Web site. [http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926\\_eng.pdf?ua=1&ua=1](http://apps.who.int/iris/bitstream/10665/179870/1/9789241508926_eng.pdf?ua=1&ua=1). Accessed October 15, 2015.
105. Duffus WA, Davis HT, Byrd MD, Heidari K, Stephens TG, Gibson JJ. HIV testing in women: missed opportunities. *J Womens Health*. 2012;21(2):170–178.
106. Centers for Disease Control and Prevention (CDC). Missed opportunities for earlier diagnosis of HIV infection—South Carolina, 1997–2005. *MMWR Morb Mortal Wkly Rep*. 2006;55(47):1269–1272.
107. Leon N, Naidoo P, Mathews C, Lewin S, Lombard C. The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. *Implement Sci*. 2010;5:8.
108. Leber W, McMullen H, Anderson J, et al. Promotion of rapid testing for HIV in primary care (RHIVA2): a cluster-randomised controlled trial. *Lancet*. 2015;2(6):e229–e235.
109. Sweat M, Morin S, Celentano D, et al. Community-based intervention to increase HIV testing and case detection in people aged 16–32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. *Lancet Infect Dis*. 2011;11(7):525–532.
110. Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. *PLoS Med*. 2012;9(7):e1001270.
111. Simaputtanasan A, Phanjaroen K, Pankam T, et al. High Uptake of Mobile HIV Testing in Bangkok Metropolitan Area, Thailand. Presented at: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; June 30–July 3, 2013; Kuala Lumpur, Malaysia.
112. Kawichai S, Celentano DD, Chariyalertsak S, et al. Community-based voluntary counseling and testing services in rural communities of Chiang Mai Province, Northern Thailand. *AIDS Behav*. 2007;11(5):770–777.
113. Lahuerta M, Sabido M, Giardina F, et al. Comparison of users of an HIV/syphilis screening community-based mobile van and traditional voluntary counselling and testing sites in Guatemala. *Sex Transm Infect*. 2011;87(2):136–140.
114. Nhurod P, Bollen LJ, Smutrapapoot P, et al. Access to HIV testing for sex workers in Bangkok, Thailand: a high prevalence of HIV among street-based sex workers. *Southeast Asian J Trop Med Public Health*. 2010;41(1):153–162.
115. Sekandi JN, Sempeera H, List J, et al. High acceptance of home-based HIV counseling and testing in an urban community setting in Uganda. *BMC Public Health*. 2011;11:730.
116. Helleringer S, Kohler HP, Frimpong JA, Mkandawire J. Increasing uptake of HIV testing and counseling among the poorest in sub-Saharan countries through home-based service provision. *J Acquir Immune Defic Syndr*. 2009;51(2):185–193.
117. Medley A, Ackers M, Amolloh M, et al. Early uptake of HIV clinical care after testing HIV-positive during home-based testing and counseling in western Kenya. *AIDS Behav*. 2013;17(1):224–234.
118. Suthar AB, Ford N, Bachanas PJ, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. *PLoS Med*. 2013;10(8):e1001496.
119. Ransome Y, Terzian A, Addison D, Braunstein S, Myers J, Nash D. Expanded HIV Testing Coverage is Ecologically Associated with Decreases in the Number of Late HIV Diagnoses, New York City, 2001–2010. Presented at: 8th International Conference on HIV Treatment and Prevention Adherence; June 2–4, 2013; Miami, FL.
120. Castel AD, Magnus M, Peterson J, et al. Implementing a novel citywide rapid HIV testing campaign in Washington, D.C.: findings and lessons learned. *Public Health Rep*. 2012;127(4):422–431.
121. Chamie G, Kwarisiima D, Clark TD, et al. Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. *PLoS One*. 2012;7(8):e43400.
122. Lugada E, Millar D, Haskew J, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. *PLoS One*. 2010;5(8):e12435.
123. Kahn JG, Harris B, Mermin JH, et al. Cost of community integrated prevention campaign for malaria, HIV, and diarrhea in rural Kenya. *BMC Health Serv Res*. 2011;11:346.
124. Kahn JG, Muraguri N, Harris B, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. *PLoS One*. 2012;7(2):e31316.
125. Hatcher AM, Turan JM, Leslie HH, et al. Predictors of linkage to care following community-based HIV counseling and testing in rural Kenya. *AIDS Behav*. 2012;16(5):1295–1307.
126. Adjei AA, Armah HB, Gbagbo F, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: a national multicenter study. *BMC Infect Dis*. 2008;8:33.
127. Arora U, Chopra S. Seropositivity of HIV infection among armed forces attending integrated testing and counseling

- centre in a tertiary care hospital. *Indian J Public Health*. 2010; 54(1):45.
128. Azuonwu O, Erhabor O, Obire O. HIV among military personnel in the Niger Delta of Nigeria. *J Community Health*. 2012;37(1): 25–31.
  129. Houdmont J, Munir F, Grey M. Acceptance of repeat worksite HIV voluntary counselling and testing in a rural South African factory. *AIDS Care*. 2013;25(9):1199–1202.
  130. Riviello ED, Sterling TR, Shepherd B, Fantan T, Makhema J. HIV in the workplace in Botswana: incidence, prevalence, and disease severity. *AIDS Res Hum Retroviruses*. 2007;23(12):1453–1460.
  131. Kalibala S, Tun W, Cherutich P, Nganga A, Oweya E, Oluoch P. Factors associated with acceptability of HIV self-testing among health care workers in Kenya. *AIDS Behav*. 2014;18(suppl 4): S405–S414.
  132. Choko AT, Desmond N, Webb EL, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre, Malawi. *PLoS Med*. 2011;8(10):e1001102.
  133. Carballo-Dieguez A, Frasca T, Balan I, Ibitoye M, Dolezal C. Use of a rapid HIV home test prevents HIV exposure in a high risk sample of men who have sex with men. *AIDS Behav*. 2012;16(7):1753–1760.
  134. Pant Pai N, Bhargava M, Joseph L, et al. Will an unsupervised self-testing strategy be feasible to operationalize in Canada? Results from a pilot study in students of a large Canadian university. *AIDS Res Treat*. 2014;2014:747619.
  135. Choko AT, MacPherson P, Webb EL, et al. One Year Outcomes Following Community-Based HIV Self-Testing: A Prospective Study in Malawi. Presented at: Conference on Retroviruses and Opportunistic Infections. March 3-6, 2014; Boston, MA.
  136. Cambiano V, Ford D, Mabugu T, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. *J Infect Dis*. 2015;212(4):570–577.
  137. Oster AM, Wejnert C, Mena LA, Elmore K, Fisher H, Heffelfinger JD. Network analysis among HIV-infected young black men who have sex with men demonstrates high connectedness around few venues. *Sex Transm Dis*. 2013;40(3):206–212.
  138. Hogben M, McNally T, McPheeters M, Hutchinson AB. The effectiveness of HIV partner counseling and referral services in increasing identification of HIV-positive individuals a systematic review. *Am J Prev Med*. 2007;33(2 suppl):S89–S100.
  139. Fuqua V, Chen YH, Packer T, et al. Using social networks to reach black MSM for HIV testing and linkage to care. *AIDS Behav*. 2012;16(2):256–265.
  140. Schneider JA, Saluja GS, Oruganti G, et al. HIV infection dynamics in rural Andhra Pradesh south India: a sexual-network analysis exploratory study. *AIDS Care*. 2007;19(9): 1171–1176.
  141. Kimbrough LW, Fisher HE, Jones KT, Johnson W, Thadiparthi S, Dooley S. Accessing social networks with high rates of undiagnosed HIV infection: the social networks demonstration project. *Am J Public Health*. 2009;99(6):1093–1099.
  142. Brown LB, Miller WC, Kamanga G, et al. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr*. 2011;56(5):437–442.
  143. Creek T, Ntuny R, Mazhani L, et al. Factors associated with low early uptake of a national program to prevent mother to child transmission of HIV (PMTCT): results of a survey of mothers and providers, Botswana, 2003. *AIDS Behav*. 2009;13(2):356–364.
  144. Panditrao M, Darak S, Kulkarni V, Kulkarni S, Parchure R. Socio-demographic factors associated with loss to follow-up of HIV-infected women attending a private sector PMTCT program in Maharashtra, India. *AIDS Care*. 2011;23(5): 593–600.
  145. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. *Arch Intern Med*. 2008; 168(11):1181–1187.
  146. Wanyenze RK, Hahn JA, Liechty CA, et al. Linkage to HIV care and survival following inpatient HIV counseling and testing. *AIDS Behav*. 2011;15(4):751–760.
  147. Christopoulos KA, Kaplan B, Dowdy D, et al. Testing and linkage to care outcomes for a clinician-initiated rapid HIV testing program in an urban emergency department. *AIDS Patient Care STDs*. 2011;25(7):439–444.
  148. MacPherson P, Lalloo DG, Choko AT, et al. Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi. *Trop Med Int Health*. 2012;17(4):507–517.
  149. Baeten J, Heffron R, Kidoguchi L, et al. Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. Presented at: Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
  150. Kaiser R, Bunnell R, Hightower A, et al. Factors associated with HIV infection in married or cohabitating couples in Kenya: results from a nationally representative study. *PLoS One*. 2011;6(3):e17842.
  151. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev*. 2002;(1): CD003255.
  152. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting [published online September 1, 2015]. *Clin Infect Dis*. 2015. pii: civ778.
  153. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS Med*. 2005;2(11):e298.
  154. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. *Lancet*. 2007;369(9562):643–656.
  155. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. *Lancet*. 2007;369(9562):657–666.
  156. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral post-exposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States:

- recommendations from the U.S. Department of Health and Human Services. *MMWR Recomm Rep*. 2005;54(RR-2):1–20.
157. Wiessing L, Likatavičius G, Klemková D, Hedrich D, Nardone A, Griffiths P. Associations between availability and coverage of HIV-prevention measures and subsequent incidence of diagnosed HIV infection among injection drug users. *Am J Public Health*. 2009;99(6):1049–1052.
  158. Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. *Int J Drug Policy*. 2007;18(4):326–328.
  159. World Health Organization. *Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach*. Geneva, Switzerland: World Health Organization; 2014. Web site. <http://www.who.int/hiv/pub/guidelines/arv2013/december2014supplementARV.pdf>. Accessed October 15, 2015.
  160. World Health Organization. *Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations*. Geneva, Switzerland: World Health Organization; 2014. Web site. [http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431\\_eng.pdf?ua=1&ua=1](http://apps.who.int/iris/bitstream/10665/128048/1/9789241507431_eng.pdf?ua=1&ua=1). Accessed October 15, 2015.
  161. Thurman TR, Haas LJ, Dushimimana A, Lavin B, Mock N. Evaluation of a case management program for HIV clients in Rwanda. *AIDS Care*. 2010;22(6):759–765.
  162. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. *Clin Infect Dis*. 2006;43(2):234–242.
  163. Craw JA, Gardner LI, Marks G, et al. Brief strengths-based case management promotes entry into HIV medical care: results of the antiretroviral treatment access study-II. *J Acquir Immune Defic Syndr*. 2008;47(5):597–606.
  164. Konate I, Traore L, Ouedraogo A, et al. Linking HIV prevention and care for community interventions among high-risk women in Burkina Faso—the ARNS 1222 “Yerelon” cohort. *J Acquir Immune Defic Syndr*. 2011;57(suppl 1):S50–S54.
  165. Hightow-Weidman LB, Jones K, Wohl AR, et al. Early linkage and retention in care: findings from the outreach, linkage, and retention in care initiative among young men of color who have sex with men. *AIDS Patient Care STDs*. 2011;25(suppl 1):S31–S38.
  166. Mugavero MJ, Norton WE, Saag MS. Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system. *Clin Infect Dis*. 2011;52(suppl 2):S238–S246.
  167. Grinsztejn B, Hosseini-pour MC, Ribaud HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis*. 2014;14(4):281–290.
  168. Cohen M, Chen Y, McCauley M. Antiretroviral Treatment Prevents HIV Transmission: Final Results from the HPTN 052 Randomized Controlled Trial. Presented at: 8th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 18–22, 2015; Vancouver, Canada.
  169. Roger A, Cambiano V, Brunn T, et al. HIV Transmission Risk through Condomless Sex if HIV+ Partner on Suppressive ART: PARTNER Study. Presented at: Conference on Retroviruses and Opportunistic Infections; March 3–6, 2014; Boston, MA.
  170. TEMPRANO ANRS. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med*. 2015;373(9):808–822.
  171. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medical Association. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents; 2015. Web site. [https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult\\_oi.pdf](https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf). Accessed October 15, 2015.
  172. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. *N Engl J Med*. 2010;362(8):697–706.
  173. World Health Organization. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2014. Web site. [http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013supplement\\_march2014/en/](http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013supplement_march2014/en/). Accessed October 15, 2015.
  174. Gale HB, Gitterman SR, Hoffman HJ, et al. Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts  $\geq 300$  cells/ $\mu$ L and HIV-1 suppression? *Clin Infect Dis*. 2013;56(9):1340–1343.
  175. Hyle EP, Sax PE, Walensky RP. Potential savings by reduced CD4 monitoring in stable patients with HIV receiving antiretroviral therapy. *JAMA Intern Med*. 2013;173(18):1746–1748.
  176. Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. *Lancet*. 2014;383(9936):2222–2231.
  177. Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: final 5-year results from STARTMRK. *J Acquir Immune Defic Syndr*. 2013;63(1):77–85.
  178. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. *Lancet*. 2012;379(9835):2439–2448.
  179. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. *N Engl J Med*. 2013;369(19):1807–1818.
  180. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label,

- phase 3b, non-inferiority trial. *Lancet Infect Dis.* 2014;14(7):581–589.
181. Pozniak A, Markowitz M, Mills A, et al. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. *Lancet Infect Dis.* 2014;14(7):590–599.
  182. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. *Clin Infect Dis.* 2014;58(9):1297–1307.
  183. U.S Department of Health and Human Services. *Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.* Bethesda, MD: U.S Department of Health and Human Services; 2014. Web site. <http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>. Accessed October 15, 2015.
  184. Young B, Hart RL, Buchacz K, Scott M, Palella F, Brooks JT. HIV viral load monitoring frequency and risk of treatment failure among immunologically stable HIV-infected patients prescribed combination antiretroviral therapy [published online August 20, 2015]. *J Int Assoc Provid AIDS Care.* 2015.
  185. Baxter JD, Dunn D, White E, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. *HIV Med.* 2015;16(suppl 1):77–87.
  186. Rhee SY, Blanco JL, Jordan MR, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. *PLoS Med.* 2015;12(4):e1001810.
  187. Kuritzkes DR, Lalama CM, Ribaud HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. *J Infect Dis.* 2008;197(6):867–870.
  188. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. *AIDS.* 2010;24(8):1203–1212.
  189. Ross L, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. *HIV Clin Trials.* 2007;8(1):1–8.
  190. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). *Antivir Ther.* 2003;8(5):427–434.
  191. Wegner SA, Wallace MR, Aronson NE, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. *Clin Infect Dis.* 2004;38(5):723–730.
  192. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. *AIDS.* 2002;16(2):209–218.
  193. Palella FJ, Jr, Armon C, Buchacz K, et al. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. *Ann Intern Med.* 2009;151(2):73–84.
  194. Hong SY, Jonas A, DeKlerk M, et al. Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. *J Acquir Immune Defic Syndr.* 2015;68(4):463–471.
  195. Kredt T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. *Cochrane Database Syst Rev.* 2013;6:CD009987.
  196. Chu C, Umanski G, Blank A, Grossberg R, Selwyn PA. HIV-infected patients and treatment outcomes: an equivalence study of community-located, primary care-based HIV treatment vs. hospital-based specialty care in the Bronx, New York. *AIDS Care.* 2010;22(12):1522–1529.
  197. Bucher JB, Thomas KM, Guzman D, Riley E, Dela Cruz N, Bangsberg DR. Community-based rapid HIV testing in homeless and marginally housed adults in San Francisco. *HIV Med.* 2007;8(1):28–31.
  198. World Health Organization. *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach.* Geneva, Switzerland: World Health Organization; 2013. Web site. [http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf). Accessed October 15, 2015.
  199. Myers JJ, Modica C, Dufour MS, Bernstein C, McNamara K. Routine rapid HIV screening in six community health centers serving populations at risk. *J Gen Intern Med.* 2009;24(12):1269–1274.
  200. Decroo T, Koole O, Remartinez D, et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. *Trop Med Int Health.* 2014;19(5):514–521.
  201. Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. *AIDS Patient Care STDs.* 2012;26(9):526–531.
  202. Henderson KC, Hindman J, Johnson SC, Valuck RJ, Kiser JJ. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. *AIDS Patient Care STDs.* 2011;25(4):221–228.
  203. Hirsch JD, Rosenquist A, Best BM, Miller TA, Gilmer TP. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medicaid beneficiaries. *J Manag Care Pharm.* 2009;15(1):32–41.
  204. Grimsrud A, Patten G, Sharp J, Myer L, Wilkinson L, Bekker LG. Extending dispensing intervals for stable patients on ART. *J Acquir Immune Defic Syndr.* 2014;66(2):e58–e60.
  205. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. *Ann Intern Med.* 1999;131(2):81–87.
  206. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. *Ann Intern Med.* 2000;133(1):21–30.



207. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. *Clin Infect Dis*. 2001;33(8):1417–1423.
208. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. *AIDS*. 2003;17(13):1925–1932.
209. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. *Clin Infect Dis*. 2003;37(8):1112–1118.
210. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. *J Infect Dis*. 2005;191(3):339–347.
211. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. *AIDS*. 2001;15(9):1181–1183.
212. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. *AIDS*. 2002;16(7):1051–1058.
213. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. *J Acquir Immune Defic Syndr*. 2006;43(1):78–84.
214. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts  $\geq 200$  cells/microl. *AIDS*. 2006;20(8):1117–1123.
215. Bachelet LT, Anton ED, Kudish P, et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. *Antimicrob Agents Chemother*. 2000;44(9):2475–2484.
216. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. *JAMA*. 2006;296(6):679–690.
217. Hu YW, Kinsler JJ, Sheng Z, Kang T, Bingham T, Frye DM. Using laboratory surveillance data to estimate engagement in care among persons living with HIV in Los Angeles County, 2009. *AIDS Patient Care STDs*. 2012;26(8):471–478.
218. Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: outcomes of the Outreach Initiative. *AIDS Patient Care STDs*. 2007;21(suppl 1):S40–S48.
219. Mugavero MJ, Davila JA, Nevin CR, Giordano TP. From access to engagement: measuring retention in outpatient HIV clinical care. *AIDS Patient Care STDs*. 2010;24(10):607–613.
220. Yehia BR, Fleishman JA, Metlay JP, et al. Comparing different measures of retention in outpatient HIV care. *AIDS*. 2012;26(9):1131–1139.
221. Mugavero MJ, Westfall AO, Zinski A, et al. Measuring retention in HIV care: the elusive gold standard. *J Acquir Immune Defic Syndr*. 2012;61(5):574–580.
222. Herwehe J, Wilbright W, Abrams A, et al. Implementation of an innovative, integrated electronic medical record (EMR) and public health information exchange for HIV/AIDS. *J Am Med Assoc*. 2012;19(3):448–452.
223. Nglazi MD, Kaplan R, Wood R, Bekker L-G, Lawn SD. Identification of losses to follow-up in a community-based antiretroviral therapy clinic in South Africa using a computerized pharmacy tracking system. *BMC Infect Dis*. 2010;10:329.
224. El-Khatib Z, Ekstrom AM, Coovadia A, et al. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa—a prospective cohort study. *BMC Public Health*. 2011;11:88.
225. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African sites with comprehensive monitoring availability. *Clin Infect Dis*. 2009;48(1):115–122.
226. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. *PLoS One*. 2012;7(3):e32993.
227. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-Report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. *AIDS Behav*. 2006;10(3):227–245.
228. Walshe L, Saple DG, Mehta SH, Shah B, Bollinger RC, Gupta A. Physician estimate of antiretroviral adherence in India: poor correlation with patient self-report and viral load. *AIDS Patient Care STDs*. 2010;24(3):189–195.
229. Murri R, Ammassari A, Trotta MP, et al. Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. *J Gen Intern Med*. 2004;19(11):1104–1110.
230. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? *J Gen Intern Med*. 2002;17(1):1–11.
231. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. *Clin Infect Dis*. 2011;52(4):493–506.
232. Saberi P, Johnson MO. Technology-based self-care methods of improving antiretroviral adherence: a systematic review. *PLoS One*. 2011;6(11):e27533.
233. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. *Lancet*. 2010;376(9755):1838–1845.
234. Pop-Eleches C, Thirumurthy H, Habyarimana JP, et al. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. *AIDS*. 2011;25(6):825–834.
235. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. *Cochrane Database Syst Rev*. 2012;3:CD009756.
236. Finitisis DJ, Pellowski JA, Johnson BT. Text message intervention designs to promote adherence to antiretroviral therapy

- (ART): a meta-analysis of randomized controlled trials. *PLoS One*. 2014;9(2):e88166.
237. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. *PLoS Med*. 2011;8(3):e1000422.
  238. Andrade AS, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. *Clin Infect Dis*. 2005;41(6):875–882.
  239. Hardy H, Kumar V, Doros G, et al. Randomized controlled trial of a personalized cellular phone reminder system to enhance adherence to antiretroviral therapy. *AIDS Patient Care STDs*. 2011;25(3):153–161.
  240. Henry SR, Goetz MB, Asch SM. The effect of automated telephone appointment reminders on HIV primary care no-shows by veterans. *J Assoc Nurses AIDS Care*. 2012;23(5):409–418.
  241. Maduka O, Tobin-West CI. Adherence counseling and reminder text messages improve uptake of antiretroviral therapy in a tertiary hospital in Nigeria. *Niger J Clin Pract*. 2013;16(3):302–308.
  242. Tuldra A, Fumaz CR, Ferrer MJ, et al. Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2000;25(3):221–228.
  243. Javanbakht M, Prosser P, Grimes T, Weinstein M, Farthing C. Efficacy of an individualized adherence support program with contingent reinforcement among nonadherent HIV-positive patients: results from a randomized trial. *J Int Assoc Physicians AIDS Care (Chic)*. 2006;5(4):143–150.
  244. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. *J Acquir Immune Defic Syndr*. 2006;41(3):285–297.
  245. de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions: a meta-analysis of randomized controlled trials. *Arch Intern Med*. 2010;170(3):240–250.
  246. Higa DH, Marks G, Crepaz N, Liao A, Lyles CM. Interventions to improve retention in HIV primary care: a systematic review of U.S. studies. *Curr HIV/AIDS Rep*. 2012;9(4):313–325.
  247. Gardner LI, Marks G, Craw JA, et al. A low-effort, clinic-wide intervention improves attendance for HIV primary care. *Clin Infect Dis*. 2012;55(8):1124–1134.
  248. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. *Clin Infect Dis*. 2007;45(7):908–915.
  249. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. *Lancet*. 2009;374(9707):2064–2071.
  250. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. *Clin Infect Dis*. 2007;45(6):770–778.
  251. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. *J Acquir Immune Defic Syndr*. 2005;39(5):545–550.
  252. Berg KM, Litwin A, Li X, Heo M, Arnsten JH. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. *Drug Alcohol Depend*. 2011;113(2-3):192–199.
  253. Tehrani ASS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community—a potential conduit to improved HIV treatment outcomes. *Contemporary Clinical Trials*. 2012;33(2):436–444.
  254. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. *Clin Infect Dis*. 2006;42(11):1628–1635.
  255. Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. *J Acquir Immune Defic Syndr*. 2009;50(2):176–181.
  256. Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. *Ann Intern Med*. 2010;152(11):704–711.
  257. Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics. *Drug Alcohol Depend*. 2012;125(3):260–266.
  258. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. *AIDS*. 2010;24(17):2665–2678.
  259. Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. *MMWR Morb Mortal Wkly Rep*. 2014;63(47):1113–1117.
  260. Alvarez-Uria G, Pakam R, Midde M, Naik PK. Entry, retention, and virological suppression in an HIV cohort study in India: description of the cascade of care and implications for reducing HIV-related mortality in low- and middle-income countries. *Interdiscip Perspect Infect Dis*. 2013;2013:384805.
  261. Ashman JJ, Conviser R, Pounds MB. Associations between HIV-positive individuals' receipt of ancillary services and medical care receipt and retention. *AIDS Care*. 2002;14(suppl 1):S109–S118.
  262. Sherer R, Stieglitz K, Narra J, et al. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. *AIDS Care*. 2002;14(suppl 1):S31–S44.
  263. Gardner LI, Giordano TP, Marks G, et al. Enhanced personal contact with HIV patients improves retention in primary care:

- a randomized trial in 6 US HIV clinics. *Clin Infect Dis*. 2014; 59(5):725–734.
264. Shrestha RK, Gardner L, Marks G, et al. Estimating the cost of increasing retention in care for HIV-infected patients: results of the CDC/HRSA retention in care trial. *J Acquir Immune Defic Syndr*. 2015;68(3):345–350.
  265. Udeagu CC, Webster TR, Bocour A, Michel P, Shepard CW. Lost or just not following up: public health effort to re-engage HIV-infected persons lost to follow-up into HIV medical care. *AIDS*. 2013;27(14):2271–2279.
  266. World Health Organization. HIV and Adolescents: Guidance for HIV testing and Counseling and Care for Adolescents Living with HIV: Recommendations for a Public Health Approach and Considerations for Policy Makers and Managers. Geneva, Switzerland: World Health Organization; 2013. Web site. [http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf). Accessed October 15, 2015.
  267. Ramirez-Avila L, Nixon K, Noubary F, et al. Routine HIV testing in adolescents and young adults presenting to an outpatient clinic in Durban, South Africa. *PLoS One*. 2012;7(9):e45507.
  268. Jaspán HB, Li R, Johnson L, Bekker L-G. The emerging need for adolescent-focused HIV care in South Africa. *Southern Afr J HIV Med*. 2009;10(4):9–11.
  269. Mathews C, Guttmacher SJ, Flisher AJ, et al. The quality of HIV testing services for adolescents in Cape Town, South Africa: do adolescent-friendly services make a difference? *J Adolesc Health*. 2009;44(2):188–190.
  270. Bikaako-Kajura W, Luyirika E, Purcell DW, et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. *AIDS Behav*. 2006;10(4 suppl):S85–S93.
  271. Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Marrero DG, Inui TS. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral therapy adherence, child well-being, and social relationships in a resource-limited setting. *AIDS Patient Care STDs*. 2010;24(10):639–649.
  272. Spiegel HM. Nondisclosure of HIV status in adolescence. *Adolesc Med State Art Rev*. 2011;22(2):277–282.
  273. Smith R, Rossetto K, Peterson BL. A meta-analysis of disclosure of one's HIV-positive status, stigma and social support. *AIDS Care*. 2008;20(10):1266–1275.
  274. Medin G, Garcia-Navarro C, Navarro Gomez M, et al. Disease disclosure, treatment adherence, and behavioural profile in a cohort of vertically acquired HIV-infected adolescents. NeuroCoRISpeS study. *AIDS Care*. 2015;1–7.
  275. Pai ALH, Ostendorf HM. Treatment adherence in adolescents and young adults affected by chronic illness during the health care transition from pediatric to adult health care: a literature review. *Child Health Care*. 2011;40(1):16–33.
  276. Fair CD, Sullivan K, Gatto A. Indicators of transition success for youth living with HIV: perspectives of pediatric and adult infectious disease care providers. *AIDS Care*. 2011;23(8):965–970.
  277. Gardner EM, Maravi ME, Rietmeijer C, Davidson AJ, Burman WJ. The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. *Appl Health Econ Health Policy*. 2008;6(2-3):145–155.
  278. Dombrowski JC, Kent JB, Buskin SE, Stekler JD, Golden MR. Population-based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. *AIDS*. 2012;26(1):77–86.
  279. Nosyk B, Montaner JS, Colley G, et al. The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study. *Lancet Infect Dis*. 2014;14(1):40–49.
  280. Institute of Medicine. Monitoring HIV Care in the United States: A Strategy for Generating National Estimates of HIV Care and Coverage. Washington, DC: Institute of Medicine; Oct 5, 2012. Web site. <http://iom.edu/Reports/2012/Monitoring-HIV-Care-in-the-United-States-A-Strategy-for-Generating-National-Estimates-of-HIV-Care-and-Coverage.aspx>. Accessed October 15, 2015.
  281. World Health Organization. Metrics for monitoring the cascade of HIV testing, care and treatment services in Asia and the Pacific. Geneva: World Health Organization; 2014. Web site. [http://www.searo.who.int/entity/hiv/hiv\\_metrics.pdf](http://www.searo.who.int/entity/hiv/hiv_metrics.pdf). Accessed October 15, 2015.
  282. National AIDS Manual. The treatment cascade; 2014. Web site. <http://www.aidsmap.com/The-treatment-cascade/page/2835702/>. Accessed October 15, 2015.
  283. Raymond A, Hill A, Pozniak A. Large disparities in HIV treatment cascades between eight European and high-income countries—analysis of break points. *J Int AIDS Soc*. 2014;17(4 suppl 3):19507.
  284. Joint United Nations Programme on HIV/AIDS (UNAIDS). Spectrum/EPP 2014; 2014. Web site. <http://www.unaids.org/en/dataanalysis/datatools/spectrumep2013>. Accessed October 15, 2015.
  285. McNairy ML, Lamb MR, Abrams EJ, et al. Use of a comprehensive HIV care cascade for evaluating HIV program performance: findings from 4 sub-Saharan African countries. *J Acquir Immune Defic Syndr*. 2015;70(2):e44–e51.
  286. Lowrance DW, Makombe S, Harries AD, et al. A public health approach to rapid scale-up of antiretroviral treatment in Malawi during 2004-2006. *J Acquir Immune Defic Syndr*. 2008;49(3):287–293.
  287. Nsanzimana S, Remera E, Kanters S, et al. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. *Lancet Glob Health*. 2015;3(3):e169–e177.
  288. Kohler P, Schmidt AJ, Cavassini M, et al. The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV. *AIDS*. 2015; Epub.
  289. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. *Lancet*. 2010;376(9737):268–284.
  290. Shannon K, Strathdee SA, Goldenberg SM, et al. Global epidemiology of HIV among female sex workers: influence of structural determinants. *Lancet*. 2014;385(9962):55–71.
  291. Weiser SD, Yuan C, Guzman D, et al. Food insecurity and HIV clinical outcomes in a longitudinal study of urban homeless and marginally housed HIV-infected individuals. *AIDS*. 2013; 27(18):2953–2958.

292. Tyler K, Melander L. The effect of drug and sexual risk behaviours with social network and non-network members on homeless youths' sexually transmissible infections and HIV testing. *Sex Health*. 2010;7(4):434–440.
293. Milloy MJ, Montaner JS, Wood E. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. *Curr HIV/AIDS Rep*. 2014;11(3):308–316.
294. Mimiaga MJ, O'Cleirigh C, Biello KB, et al. The effect of psychosocial syndemic production on 4-year HIV incidence and risk behavior in a large cohort of sexually active men who have sex with men. *J Acquir Immune Defic Syndr*. 2015;68(3):329–336.
295. Michalopoulos LM, Aifah A, El-Bassel N. A systematic review of HIV risk behaviors and trauma among forced and unforced migrant populations from low and middle-income countries: state of the literature and future directions. *AIDS Behav*. 2015. Web site. <http://link.springer.com/article/10.1007/s10461-015-1014-1>. Accessed October 15, 2015.
296. Des Jarlais DC, McCarty D, Vega WA, Bramson H. HIV infection among people who inject drugs: the challenge of racial/ethnic disparities. *Am Psychol*. 2013;68(4):274–285.
297. Earnshaw VA, Bogart LM, Dovidio JF, Williams DR. Stigma and racial/ethnic HIV disparities: moving toward resilience. *Am Psychol*. 2013;68(4):225–236.
298. Des Jarlais DC, Bramson HA, Wong C, et al. Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis. *Addiction*. 2012;107(12):2087–2095.
299. Chan KY, Stooze MA, Sringeriyuang L, Reidpath DD. Stigmatization of AIDS patients: disentangling Thai nursing students' attitudes towards HIV/AIDS, drug use, and commercial sex. *AIDS Behav*. 2008;12(1):146–157.
300. Genberg BL, Hlavka Z, Konda KA, et al. A comparison of HIV/AIDS-related stigma in four countries: negative attitudes and perceived acts of discrimination towards people living with HIV/AIDS. *Soc Sci Med*. 2009;68(12):2279–2287.
301. Shannon K, Csete J. Violence, condom negotiation, and HIV/STI risk among sex workers. *JAMA*. 2010;304(5):573–574.
302. Kouyoumdjian FG, Findlay N, Schwandt M, Calzavara LM. A systematic review of the relationships between intimate partner violence and HIV/AIDS. *PLoS One*. 2013;8(11):e81044.
303. Eaton LA, Driffin DD, Kegler C, et al. The role of stigma and medical mistrust in the routine health care engagement of black men who have sex with men. *Am J Public Health*. 2015;105(2):e75–e82.
304. Palepu A, Milloy MJ, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. *J Urban Health*. 2011;88(3):545–555.
305. Dickson-Gomez J, Owczarzak J, St Lawrence J, et al. Beyond the ball: implications for HIV risk and prevention among the constructed families of African American men who have sex with men. *AIDS Behav*. 2014;18(11):2156–2168.
306. Nelson P, Mathers B, Cowie B, et al. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. *Lancet*. 2011;378(9791):571–583.
307. Jittimane SX, Nateniyom S, Kittikraisak W, et al. Social stigma and knowledge of tuberculosis and HIV among patients with both diseases in Thailand. *PLoS One*. 2009;4(7):e6360.
308. Kerr T, Fairbairn N, Hayashi K, et al. Difficulty accessing syringes and syringe borrowing among injection drug users in Bangkok, Thailand. *Drug Alcohol Rev*. 2010;29(2):157–161.
309. Garfein RS, Golub ET, Greenberg AE, et al. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. *AIDS*. 2007;21(14):1923–1932.
310. Hayashi K, Wood E, Wiebe L, Qi J, Kerr T. An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. *Int J Drug Policy*. 2010;21(5):418–421.
311. Broadhead RS, Heckathorn DD, Weakliem DL, et al. Harnessing peer networks as an instrument for AIDS prevention: results from a peer-driven intervention. *Public Health Rep*. 1998;113(suppl 1):42–57.
312. Robertson AM, Rangel MG, Lozada R, Vera A, Ojeda VD. Male injection drug users try new drugs following U.S. deportation to Tijuana, Mexico. *Drug Alcohol Depend*. 2012;120(1-3):142–148.
313. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. *Lancet*. 2010;376(9738):355–366.
314. Wood E, Werb D, Kazatchkine M, et al. Vienna Declaration: a call for evidence-based drug policies. *Lancet*. 2010;376(9738):310–312.